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DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential as a novel therapeutic target. Using the crystal structure of human PARG in complex with the weakly active and cytotoxic anthraquinone 8a, novel quinazolinedione sulfonamides PARG inhibitors have been identified by means of structure-based virtual screening and library design.  1-Oxetan-3-ylmethyl derivatives 33d and 35d were selected for preliminary investigations in vivo. X-ray crystal structures help rationalize the observed structure-activity relationships of these novel inhibitors. 
INTRODUCTION
Exploiting the DNA damage response for cancer therapy relies on the fact that rapidly proliferating cancer cells have higher incidences of DNA damage, defective DNA repair pathways, genomic instability, or a combination of these facets.​[1]​,​[2]​,​[3]​ Poly(ADP-ribosylation) is a post-translational modification that plays an important role in the repair of damaged sections of DNA.​[4]​,​[5]​,​[6]​ Poly(ADP-ribose) polymerases (PARPs), in particular PARP1, signal the presence of DNA damage and facilitate DNA repair (Figure 1). Upon DNA damage, PARP1 binds to single-strand break (SSB) sites and autoribosylates using NAD+ as a substrate, to form poly(ADP-ribose) (PAR) chains. These PAR chains serve to recruit DNA repair proteins, such as XRCC1, to the site of DNA damage. Poly(ADP-ribose) glycohydrolase (PARG) systematically degrades the ADP-ribose polymers on the PARP enzyme, which is essential for DNA repair to occur; however, the precise order of events in this catalytic cycle is still unknown. Figure 1 shows how inhibiting PARG leads to the persistence of PAR chains, with predicted consequences on NAD recycling, PARP recycling, and SSB repair. Although PARP inhibitors have received much attention as cancer therapies,​[7]​,​[8]​ with olaparib approved by the FDA,​[9]​ the dearth of selective, cell-permeable small molecule PARG inhibitors has hampered assessment of the therapeutic potential of targeting PARG in human cancer.​[10]​,​[11]​ Additionally, whilst there are 17 known PARP family members, of which only a subset are inhibited by the PARP inhibitors, no close homologs of PARG exist.4 This provides an attractive target for drug discovery, given the cell’s apparent reliance on this single enzyme in nuclear DNA damage repair.​[12]​

Figure 1. Consequences of PARG inhibition in DNA SSB repair 
Crystal structures of the bacterial, protozoal, and mammalian PARG catalytic domains have served to elucidate the structural basis of PAR substrate recognition and catalytic mechanism.​[13]​,​[14]​,​[15]​,​[16]​,​[17]​,​[18]​,​[19]​ The C-terminal catalytic domain of PARG comprises a macrodomain, an evolutionarily conserved subunit that binds ADP-ribose and is involved in the regulation of PAR turnover and signalling,​[20]​ with a PARG-specific catalytic loop. PARG demonstrates a preference for hydrolyzing the long, unbranched chains of PAR, which interact with an extended substrate binding site that is mostly solvent-exposed and polar in character. 
To date, identification of potent and selective PARG inhibitors has been hampered by the lack of a suitable HTS-compatible assay system, prompting our recent development of a robust Homogeneous Time-Resolved Fluorescence (HTRF) based assay format.​[21]​ Inhibitors reported in the literature include: ADP-ribose mimetics (e.g., ADP-HPD, 1),​[22]​ tannins (e.g., mono-galloyl glucose, 2),​[23]​ salicylanilides (3),​[24]​ rhodanine-based compounds (4),​[25]​ and phenolic hydrazide hydrazones (5)​[26]​ (Figure 2). These compounds are typically weakly potent, non-specific inhibitors with poor cell permeability, only demonstrating activity in cell lysates.11 For example, compounds 3 and 4 did not demonstrate significant PARG inhibitory activity in our biochemical assay (activities > 70 µM in our hands). Although compound 4 contains the known pan-assay interference (PAINs)​[27]​ motif rhodanine, it has been successfully crystallized in complex with protozoal PARG, demonstrating binding to the ADP-ribose site.24

Figure 2. Reported PARG inhibitors
Given the lack of drug-like, cell permeable inhibitors reported to date, there remains a need for selective tool compounds with improved physicochemical properties to validate the therapeutic potential of PARG inhibition.11 To address this need, we recently reported the first cell-active chemical probes against this enzyme.12,​[28]​,​[29]​ Herein, we describe the early discovery of several novel lead-like chemotypes arising from a programme of virtual screening and structure-guided library design, inspired by the crystal structure of a weakly active HTS hit bound to human PARG. We further report our efforts to optimize one of these chemotypes in order to afford more potent in vitro tool compounds, and derivatives with physicochemical properties suitable for preliminary in vivo pharmacokinetic (PK) assessment.
CHEMISTRY
For preliminary hit expansion, compounds were generally prepared using traditional chlorosulfonation techniques to prepare the sulfonyl chloride, which was then used for sulfonamide formation. Anthraquinones 8ao were prepared in this manner as detailed in Scheme 1, as was compounds 16 described in Scheme 3, with purification by preparative HPLC leading to variable recoveries of material. Symmetrically substituted quinazolinediones 12ac, 13a,b were prepared by alkylation of the quinazolinedione, followed by chlorosulfonation and sulfonamide formation (Scheme 2). For the unsymmetrically substituted quinazolinediones 22ah, a route was developed which installed the acetyl protected alkyl sulfonamide and allowed diversification in the final step, as detailed in Scheme 4.
Scheme 1:a Synthesis of analogues 8ao

aReagents: a) SOCl2, DMF, reflux, 53%; b) RNH2, Et3N, DCM, 15%quant.
Scheme 2:a Synthesis of 12ac, 13a,b
 aReagents: a) RI, K2CO3, DMF, 3041%; b) ClSO3H, 60 C, 6467%; c) R’NH2, Et3N, DCM, 1876%.
Scheme 3:a Synthesis of 16

aReagents: a) ClSO3H, 60 C, 70%; b) RNH2, i-Pr2NEt, THF, DCM, 43%. 
Scheme 4:a Synthesis of Analogues 22at

 aReagents: a) CDI, DMF, 140 C, 90%; b) ClSO3H, 60 C, 99%; c) 1-methylcyclopropanamine hydrochloride, Et3N, DCM, 89%; d) Ac2O, pyridine, DMAP, 83%; e) BrCH2CN, Cs2CO3, DMF, 75%; f) R-X (where X = I or Br), K2CO3, DMF, then NH3, THF, 28-88%; g) R-X (where X = Cl, Br or I), K2CO3, DMF, then K2CO3, MeOH 2032%; h) R-OH, DIAD, PS-PPh3, DMF, then K2CO3, MeOH, 93%. 
Scheme 5 describes the synthesis of 27a–au, with elaboration at the N3 vector. The quinazolinedione core was formed from N-methylanthranilic acid and sodium cyanate. Subsequent chlorosulfonylation and sulfonamide formation afforded key intermediate 26, which was alkylated to give 1-methyl-3-substituted quinazolinediones 27a-au. Scheme 6 shows the synthesis of quinazolinediones with elaboration at both N1 and N3 vectors. Chlorosulfonylation of isatoic anhydride afforded 30. Careful temperature control in the subsequent sulfonamide formation was vital to minimize anhydride ring-opening with amine 28. Once the sulfonamide formation was complete at a low temperature, the appropriate primary amine was added to the reaction mixture and warmed to room temperature (RT) to induce anhydride ring-opening and decarboxylation to give amide intermediates 31a–d. Ring closure to afford quinazolinediones 32a–d was carried out using triphosgene, and subsequent alkylation at N1 afforded compounds 33–36. In some cases, Mitsunobu reaction using diisopropylazodicarboxylate (DIAD) resulted in an inseparable mixture of product and reduced DIAD by-product. Fortunately, this problem was surmounted by using di-(4-chlorobenzyl)azodicarboxylate (DCAD),​[30]​ as the hydrazine by-product in this case is easily removed by trituration. The approach to 3-(5-methyl-1,3,4-thiadiazol-2-yl)methyl quinazolinediones 41a and 41e was slightly different (Scheme 7). The 3-substituent bearing the thiadiazole was introduced prior to the chlorosulfonylation reaction as there are no free sites on the five-membered heteroaryl ring that can undergo chlorosulfonylation in this case.
Scheme 5: Synthesis of 27a–ata

aReagents and conditions: (a) NaOCN, NaOH, AcOH, H2O, 50 °C, 1 h, 79%; (b) ClSO3H, 50 °C, 16 h, quant.; (c) amine 28, Et3N, DCM, RT, 3 h, 93%; (d) (i) NaH, DMF, RT, 5 min, (ii) R-X (X= Br, Cl, I, OTs), RT, 6–59%; (e) R-OH, DIAD (or DCAD), PS-PPh3, DMF, RT, 10–21%; (f) R-B(OH)2, Cu(OAc)2, Et3N, 4Å molecular sieves, DCM, RT, 18%.

Scheme 6: Synthesis of 33–36a

aReagents and conditions: (a) ClSO3H, 50 °C, 4 h, 79%; (b) (i) amine 28, Et3N, DCM, −10 °C, 30 min, (ii) R2-NH2, Et3N, −10 °C–RT, 18 h, 20–67%; (c) triphosgene, THF, 0 °C–RT, 18 h 78–97%; (d) (i) NaH, DMF, RT, 5 min, (ii) R1-X (X= Br, I, OMs, OTs), RT; (e) R1-OH, DIAD (or DCAD), PS-PPh3, DMF, RT, 16–75%.

Scheme 7: Synthesis of 41a and 41ea

aReagents and conditions: (a) amine 42, Et3N, DMF, 60 °C for 5 h, then RT for 16 h, 65%; (b) triphosgene, THF, 0 °C–RT, 18 h, 58%; (c) ClSO3H, 50 °C, 2 h, 69%; (d) amine 28, Et3N, DCM, 0 °C–RT, 18 h, 32%; (e) EtI, K2CO3, DMF,  µW, 80 °C, 20 min, 20% for 41a; and 5-(chloromethyl)-1,3-dimethyl-1H-pyrazole, K2CO3, DMF,  µW, 80 °C, 20 min, 44% for 41e.
RESULTS AND DISCUSSION 
Crystallographic binding mode and initial optimization of anthraquinone 8a
The low druggability of PARG was highlighted by a high-throughput screen at AstraZeneca, comprising 1.4 million compounds, which resulted in only three confirmed hits of related chemical structure, exemplified by the anthraquinone derivative 8a (Figure 3). Despite this compound’s modest inhibitory potency (EC50 = 81 µM) in an HTRF biochemical assay, we were encouraged by its approximately equipotent activity in an acute (1 h) cell-based proof-of-mechanism PAR chain persistence assay,21,​[31]​ where the compound was shown to block the PARG-mediated degradation of PAR chains in a dose-dependent manner.   However, the limited solubility of the compound precluded an accurate estimation of EC50, and further progression of this anthraquinone derivative was additionally hampered by the observation of non-specific 72 h cytotoxicity at cell-active doses.

Figure 3. Anthraquinone HTS hit 8a.
Determination of the co-crystal structure of 8a with the catalytic domain of human PARG at 1.9 Å resolution confirmed the direct interaction of the inhibitor with the PAR binding site, and revealed some unexpected binding contacts that prompted our efforts to pursue structure-guided optimization of this series. As was previously reported, the substrate binding site in human PARG comprises an extended, relatively solvent-exposed channel.15, 16 The anthraquinone 8a is observed to bind in the region occupied by the adenine moiety of the truncated PAR analogue, ADP-ribose (Figure 4). However, the plane of the anthraquinone ring system is oriented approximately orthogonal to that of the adenine moiety of ADP-ribose, with the result that 8a is highly solvent-exposed compared to the relatively well-buried adenine. The significant difference in the shape of the binding site between the two crystal structures can be attributed to Phe902 adopting a different rotamer when bound to 8a compared with ADP-ribose (Figure 4C). As a consequence, the anthraquinone core of 8a is able to form extensive face-to-face aromatic stacking interactions with both Phe902 and Tyr795. Although this rotamer of Phe902 is incompatible with substrate binding, in the published apo structure of human PARG (PDB 4A0D) both rotamers of Phe902 are observed, highlighting the flexibility of this side chain.16 
   
Figure 4. Comparison of the X-ray crystal structures of the catalytic domain of (A) human PARG bound to 8a (PDB accession code 6HMM) and (B) ADP-ribose (PDB 4B1H), shown in the same coordinate frame. Protein solvent-accessible surfaces are coloured by electrostatic potential. (C) Detail of relative binding orientations of 8a (cyan carbon atoms) and ADP-ribose (green) highlights movement of Phe902. (D) 8a and ADP Ribose bound to entire PARG domain, colored by atom type.
The binding mode of 8a is anchored by a network of three hydrogen bonds from the sulfonamide moiety to the sidechain of Glu727 and the backbones of Ile726 and Gln754, with the tert-butyl group deeply buried in a mainly hydrophobic cavity (Figure 5). We note that in the crystal structure of PARG in complex with ADP-ribose, the adenine moiety forms hydrogen bonds to the Glu727 sidechain and Ile726 backbone NH (as well as, several water-mediated contacts); hence, this is a rare example of a sulfonamide moiety mimicking the hydrogen-bond network of adenine.
    
Figure 5. (A) Detail of the hydrogen-bonding environment around 8a (PDB accession code 6HMM). (B) Protein solvent-accessible surface highlights the exposure to solvent of the anthraquinone core and the buried pocket around the tert-butyl moiety. Hydrogen atoms modelled using Maestro (Schrödinger LLC). (C) Protein-ligand interaction diagram with hydrogen bonds indicated by pink arrows and aromatic interactions by green arrows.




Table 1.a Initial optimization of the sulfonamide N-alkyl moiety of 8a







8f	Cyclopropyl	13 (5.3)	 22 (6.8)
8g	Cyclobutyl	>50b	nd
8h	1-methylcyclopropyl	6.0 (2.3)		6.6 (3.5)








aBiological data are stated as the geometric mean of at least three independent determinations unless otherwise stated, with standard deviations quoted in parentheses. nd = not determined.
bMaximum concentration limited by interference and/or solubility issues.

Scaffold-hopping by virtual screening and library design
In parallel with elaboration of the anthraquinone sulfonamide moiety, a structure-based virtual screening campaign was initiated to identify alternatives to the anthraquinone ring system that might obviate the observed cell toxicity and prove more amenable to optimization. As the hydrogen-bonding network observed around the sulfonamide appeared to be a key pharmacophore, we decided to retain this moiety while exploring alternative bi- and tricyclic ring systems that would maintain the observed stacking interactions with Tyr795 and Phe902, and introduce more drug-like physical properties. 
To this end, commercially available screening libraries were initially triaged to identify and select all aryl sulphonamides bearing a variety of aliphatic N-substituents.  These selections were then filtered for suitable drug-like properties and any PAINS or undesirable structural motifs removed. These approaches yielded around thirty one thousand putative hits which were then docked into the induced cavity observed in the X-ray structure of 8a bound to human PARG (Glide SP docking, Schrodinger, LLC, New York). Manual inspection of the top 5 docking poses per ligand ensured maintenance of the key sulphonamide binding motif and credible binding modes and from this manual analysis, a set of 68 compounds was selected for purchase and assessment, based on an assessment of binding mode, site complementarity and docking score. 









aBiological data are stated as the geometric mean of at least three independent determinations, with standard deviations quoted in parentheses. 

To determine if the weak level of activity for these compounds was a consequence of sub-optimal N-alkyl substitution on the sulfonamide, analogues of selected cores were synthesized with the preferred N-alkyl substituents identified from the optimization of 8a, e.g., methylcyclopropyl and cyanocyclopropyl (Scheme 2 and Scheme 3, Table 3). This modification resulted in a significant gain in biochemical activity for the quinazolinediones 12b, 12c, 13a and 13b, which demonstrated a greater than 20-fold improvement compared with the tert-butyl analogue 12a, and were accompanied by an increase in biochemical lipophilic ligand efficiency (LLE)​[33]​ from a value of 2.1 for 12a to 3.9 and 4.7 for 12b and 12c, respectively. Notably, the quinazolinediones also demonstrated a similar level of potency in the cell assay, with the best examples achieving low micromolar potency. However, N-methylcyclopropyl derivatives of other ring systems such as the naphthalene 16 did not achieve levels of activity to justify further consideration. From docking studies, the quinazolinedione scaffold hop was predicted to achieve very similar binding modes to the anthraquinone 8a, while offering different vectors for enhancing binding affinity through additional protein interactions (Figure 6).

Table 3.a Optimization of sulfonamide N-alkyl groups for hits from the first round of virtual screening.











 Figure 6. Predicted binding modes of quinazolinedione 12b (docked into PDB accession code 6HMM) The N1 position presents a vector towards solvent and the shelf adjacent to Phe902, while the N3 position presents a vector toward the pocket occupied by the ribose moiety of ADP. 
The requirement for specific N-alkyl sulfonamide substituents, such as tert-butyl and cyclopropyl, in order to achieve significant levels of potency suggested that potentially useful scaffold hops may have been missed in the original virtual screening campaign because of the limited commercial availability of appropriate sulfonamides. Therefore, a second round of virtual screening was initiated based on docking virtual libraries generated from the in silico enumeration of a diverse set of commercially available aryl sulfonyl chlorides with several of our preferred alkyl amines. A further set of scaffold hops was designed on the basis of 2D similarity to the active cores identified previously. Synthesis of selected examples from these approaches resulted in a chemically diverse set of additional scaffolds, several of which displayed promising levels of activity, though none proved to be superior in potency or lipophilic ligand efficiency to the quinazolinediones (Supporting Information Table S2). Note that for synthetic expediency, no attempt was made to optimize fully the substituents around each distinct ring system; rather, the aim of the exercise was to perform a rapid exploration of synthetically tractable SAR to understand whether any particular ring systems were significantly favored or disfavored.  In general, we observed that fully aromatic/delocalized bicyclic cores were preferred over partially saturated ring systems, consistent with the modelled binding modes in which the aromatic core is tightly stacked between Tyr795 and Phe902. Among aromatic systems, there appears to be a preference for one or more hydrogen bond acceptor groups such as a carbonyl oxygen (as in the quinazolinedione 12b) or a nitrogen lone pair (as in the quinoline S12, Supporting Information Table S2).  In contrast, incorporation of a nitrogen atom in the benzo ring bearing the sulfonamide resulted in between 3 and 5-fold loss of activity (e.g., compound S1, Supporting Information Table S2). We note that, in the X-ray crystal structure of PARG in complex with 8a, a number of polar protein atoms are located in close proximity to the anthraquinone ring system, including the potential hydrogen bond donor Tyr795 OH, and it may be that a combination of hydrogen bonding (perhaps through water) and enhanced π-stacking interactions account for the preferences seen for certain ring systems over others. 
Overall, by utilizing this approach, we succeeded in moving from an unattractive HTS hit to several lead-like scaffolds displaying improved ligand efficiency and physicochemical properties. Comparison of the initial hit compound 8a with 12b reveals a reduction in molecular weight and LogP, with associated increases in LE and LLE (Table 4). In addition, the scaffold hop is devoid of the acute non-specific cytotoxicity of the parent anthraquinone. On the basis of its promising potency, synthetic tractability and favorable physicochemical profile, the quinazolinedione series was prioritized as an attractive starting-point for further optimization. 
Table 4. Comparison of measured and predicted physicochemical properties of representative compounds.




aXlogP calculated using Dotmatics Elemental package (Dotmatics, Bishops Stortford, UK). bLigand Efficiency calculated from biochemical EC50 (i.e., LE = 1.4(pEC50)/HAC, where HAC is the number of heavy atoms). cRef 33. nd = not determined.
Optimization of quinazolinedione N1 position 
Initial exploration of the SAR around the quinazolinedione ring system focused on substitution at the N1 position (Scheme 4), as this vector presented an opportunity for interaction with a solvent-exposed shelf adjacent to Phe902 (Figure 6). Methylene-linked saturated and aromatic ring systems were of interest as a strategy to improve binding affinity, as modelling suggested these would readily access the Phe902 shelf; while more conformationally flexible groups were deemed likely to extend into solvent and thus, would be more useful to modulate physicochemical properties.
In general, substitution at N1 yielded relatively modest gains in biochemical and cellular EC50, (Table 5) with the ethyl analogue 22a similar in potency to the parent methyl 12b. Incorporation of more polar groups, such as in 22b and 22c, resulted in low micromolar compounds with improved LLE. We were pleased to observe that simple lipophilic groups such as the prop-2-ynyl 22d and cyclopropylmethyl 22f yielded our first sub-micromolar compounds in both enzyme and cell assays. This level of cellular potency represents a significant advance in the identification of cell-active PARG tool compounds when compared with our original HTS hit and also other inhibitors described in the literature. 
In comparison with 22f, larger carbocyclic substituents (e.g., 22g and 22h) did not result in any further gain in potency. The predicted binding mode of the benzylic derivative 22h was confirmed by soaking the compound into pre-formed crystals of human PARG, resulting in a 2.9 Å resolution X-ray crystal structure (Figure 7). The compound was observed to bind similarly to 8a, with the quinazolinedione ring system well aligned with the anthraquinone of 8a and forming aromatic stacking interactions with Tyr795 and Phe902. The sulfonamide moiety forms the same network of three hydrogen bonds as observed for 8a, with the N-methylcyclopropyl group occupying a similar location to the tert-butyl of 8a. As these groups are very similar in size, the significant improvement in activity observed for the methylcyclopropyl may be due to the greater π-character of the cyclopropyl ring:​[34]​ we note close non-bonded contacts between the cyclopropyl ring and the sidechains of Gln754 and Glu727, with a potential CH...O hydrogen bond to the backbone carbonyl of Gln754. The N1 benzyl group partly occupies the Phe902 shelf, stacking against the Phe902–Gly903 peptide bond. The interaction between the benzyl group and the Phe902 shelf appears sub-optimal in terms of shape complementarity, which likely accounts for the modest potency of 22h and suggested opportunities for further optimization.  Pleasingly, the determined crystallographic structure of this derivative closely matched the binding mode predicted by modelling, facilitating the prioritization of latter derivatives (such as the improved analogue 22f) for synthesis and precluding the requirement for extensive iterative crystallographic determination.

    
Figure 7. X-ray crystal structure of 22h bound to the catalytic domain of human PARG at 2.9 Å resolution (PDB accession code 6HMN) (A) Interaction of the N1-benzyl moiety with the Phe902 shelf. (B) Detail of the hydrogen-bonding environment around the sulfonamide, with a putative CH…O interaction highlighted by the cyan dashed line. Hydrogen atoms modelled using Maestro  (Schrödinger LLC). (C) Ligand interaction diagram coloured as in Figure 5.





22a	ethyl	1.3 (1.9)	3.6 (1.3) 
22b	2-methoxyethyl	1.1 (0.13)	6.1 (3.1) 






aBiological data are stated as the geometric mean of at least three independent determinations, with standard deviations quoted in parentheses. nd = not determined.
We determined to further investigate structure-activity relationships (SAR) at the N1 position of the quinazolinedione, as this vector presented a good opportunity for interaction with a solvent-exposed shelf adjacent to Phe902. It can be seen from the crystal structure of 22h in complex with PARG that the N1 vector projects away from the PARG active site towards solvent (Figure 7). A library of more elaborate N1-quinazolinediones (with N3 fixed as methyl) was therefore synthesized to explore whether the interactions with this shelf could be optimized in order to boost affinity. Further N1 variations are also shown in Table 6.

















aBiological data are stated as the geometric mean of at least three independent determinations, unless otherwise stated, with standard deviations quoted in parentheses. 

The results in Table 6 show that substitution at the 4-position of the phenyl ring of the benzyl derivatives was usually favored over the 2- or 3-substituted analogues. Although the SAR was generally quite flat, only modest improvements in potency were observed compared to the parent N1-benzyl analogue 22h. No improvement was observed with pyridylmethyl derivatives 22o-q. However, significant improvements were obtained with methylene-linked 5-membered heteroaryl substituents. Pyrazole derivative 22r showed low micromolar activity, and this was enhanced further by methylation at the 3-positon (22s).  Bis-methylated thiazole derivative 22t gave the most potent quinazolinedione in the series. Modelling suggested that these substituted 5-membered heterocycles achieved improved lipophilic contacts with the Phe902 shelf compared with benzyl derivative 22h. Although some polar protein sites are accessible in this region, it was not apparent from the SAR that any productive hydrogen-bonding interactions were being achieved.  
Exploring the N3 vector
We then turned our attention to exploring the SAR at the N3 vector of the quinazolinedione. Although this vector also points primarily towards solvent, its proximity to the ribose binding pocket suggested that additional productive binding interactions may be achievable. A library with a range of substituents at N3 (with N1 fixed as methyl) was modelled into the crystal structure of PARG (PDB accession code 6HMN), and a selection of analogues was prepared in order to investigate what is tolerated at this position. A representative set of N3 variations is shown in Table 7.
Table 7. Elaboration at the N3 vector
























aAll EC50 data are means of at least n = 4 independent measurements, with standard deviations quoted in parentheses.
We initially investigated lipophilic alkyl and aryl groups, and found that these gave either no improvement over the 3-methyl analogue 12b, or were detrimental to activity, consistent with the generally polar nature of the protein surface in this region. However, introducing polarity to the substituent at the N3-position yielded promising compounds with activity in the low micromolar range (e.g., 27g, 27i, 27j and 27l). Modelling studies suggested that the hydrogen bond acceptor atom common to these groups may form a hydrogen bond with Asn869. The difference in activity observed across the pyridyl isomers suggested that the position of this hydrogen bond acceptor was important, and this was further demonstrated using a series of methylene-linked heterocyclic substituents at N3. Initial exploration with this motif resulted in moderate potencies. However, moving from thiazol-2-ylmethyl derivative 27r (13 μM) to thiazol-5-yl isomer 27s resulted in a 10-fold improvement in potency to 1.2 μM. Methylation of the thiazole (27t) gave a further boost to potency to yield a sub-micromolar inhibitor. 
Determination of the X-ray crystal structure of 27t bound to the human PARG catalytic domain revealed that the quinazolinedione sulfonamide exhibited a similar binding mode to that observed for the N1-benzyl derivative 22h (Figure 8). The N3 substituent of 27t accesses a narrow solvent-exposed ledge above Phe902, potentially making a favorable edge-to-face stacking interaction with the Phe902 sidechain. The crystal structure confirmed the hypothesis that the N atom in the thiazole ring can make a hydrogen bond interaction with the Asn869 sidechain, as had been suggested by modelling. This explains the noticeable gain in potency for this specific thiazole isomer compared to other heterocycles lacking an appropriately positioned hydrogen bond acceptor (e.g., 27q). The reduced affinity noted for furan 27n and oxazole 27q is in line with the weaker hydrogen bonding strength expected from an aromatic oxygen atom compared with a nitrogen lone pair. The 2-methyl group on the thiazole ring of 27t makes an additional hydrophobic contact with the β-carbon of the Asp904 sidechain. Overall, this data suggests that the complementarity in shape and properties of the 2-methylthiazole substituent enables productive binding to an apparently unpromising, narrow shelf on the protein surface. The relatively limited conformational flexibility around the N3 methylene, due to the steric restrictions imposed by the adjacent carbonyl oxygens of the quinazolinedione core, may also help to stabilize the observed binding mode.
 
Figure 8. (A) Crystal structure of 27t bound to human PARG at 2.06 Å resolution (PDB accession code 6HMK). Hydrogen atoms modelled using Maestro (Schrödinger LLC); (B) Protein-ligand interaction diagram with hydrogen bonds indicated by pink arrows and aromatic interactions by green arrows.
The data in Table 7 indicated that the SAR at the N3 vector of the quinazolinedione was steeper than at the N1 vector. Changing the position of the nitrogen atom in the heteroaryl ring evidently had a significant effect on the PARG activity, and we were keen to explore the interaction of the nitrogen with Asn869 further. A focused set of quinazolinediones substituted at the N3 position with methylene-linked 5-membered N-containing heterocycles was therefore synthesized (Table 8).
Table 8. Exploring the interaction with Asn869: focused N3 library





























aAll EC50 data are means of at least n = 4 independent measurements, with standard deviations quoted in parentheses.
The X-ray crystal structure of 27t bound to PARG (Figure 8) showed that the methyl group on the thiazole ring was in close contact with the β-carbon of the sidechain of Asp904. The protein surface in this region is relatively polar due to the proximity of the carboxylate moiety of Asp904, as well as the backbone carbonyls of Thr901 and Phe902; hence, we hoped that the introduction of a more polar substituent in place of the methyl group would allow formation of an additional hydrogen bond. Disappointingly, however, aminothiazole 27u showed no improvement in potency compared to 27t. Methylation at the 4-position of the thiazole (27v) was tolerated with only a modest loss in PARG inhibitory activity, while the 4-phenyl analogue 27w resulted in a significant reduction in activity, likely due to steric clashes with both the protein and the quinazolinedione core. Having prepared a broad range of methylene-linked heteroaryl substituents, we observed that the best examples (with activities <0.5 μM) contained a nitrogen atom at the position essential for maintenance of the key hydrogen bond interaction with Asn869. The importance of having the correct orientation of the nitrogen lone pair is demonstrated by the striking differences in PARG activity observed between regioisomer pairs 27ah and 27ai, and 27an and 27ao. Although des-methyl analogue 27aj showed a similar biochemical activity to 27ai, it displayed a significant drop-off in cell activity (data not shown), probably due to low permeability. Overall, 3-pyrazolylmethyl and 3-isoxazolylmethyl substituents emerged as interesting, less lipophilic alternatives to the 3-thiazolylmethyl substituent of 27t. Interestingly, introduction of a nitrogen lone pair ortho to the methylene linker is generally detrimental to PARG activity (e.g., 27y, 27ad, 27ae, 27ah, 27ao and 27ar), likely as a result of conformational strain due to the unfavorable electrostatic interaction of the lone pair with the carbonyl oxygen atoms of the quinazolinedione core in the bound conformation.
Figure 9 summarizes the key SAR at the N3 vector of the quinazolinedione. A methylene-linked 5-membered heterocycle has been used as an example, however, the model is equally applicable to 3-substituents containing pyridyl (27g), ketone (27i and 27j), and nitrile (27l) functional groups. As noted earlier, overall the SAR is much steeper at the quinazolinedione N3 vector compared to the N1 vector, with specific pendant functional groups enabling a significant boost in PARG inhibition.

Figure 9. Key SAR at the 3-position of the quinazolinedione
Simultaneous elaboration at both the N1 and N3 vectors
With a better understanding of the SAR at the N1 and N3 vectors in isolation, we next investigated the effect of combining the optimized N1 and N3 substituents in the same compound in a bid to further increase potency. A representative set of N1,N3-substituted quinazolinediones is shown in Table 9.
Table 9. Simultaneous elaboration at both N1 and N3 vectors























aAll biochemical and cellular EC50 data are means of at least n = 4 independent measurements, with standard deviations quoted in parentheses; bhuman microsomal clearance (mouse microsomal clearance is shown in brackets for selected compounds); cin vitro tool compound 34e (PDD00017273)​[35]​ is available to purchase; d34f has previously been reported as PDDX-04/PDD00017272​[36]​ 
Combining substitution at both N1 and N3 vectors led to a significant improvement in potency, and biochemical EC50s as low as 4.8 nM were achieved (compound 34f). For 3-pyrazolylmethyl quinazolinediones (33a–f) up to a 100-fold increase in potency was achieved over the 1-methyl analogue (27ai). Pleasingly, in our cellular proof-of-mechanism PAR chain persistence assay,31 the inhibition of PARG in cells was in line with the biochemical EC50 values.​[37]​ 
The X-ray crystal structure of 33f was solved in complex with the catalytic domain of human PARG (Figure 10), and revealed the same binding configuration of the quinazolinedione core and sulfonamide as observed for 27t. For 33f, the N1 and N3 substituents adopt a “pincer” configuration around the Phe902 sidechain. The pyrazole nitrogen makes the key hydrogen bonding interaction with Asn869, and the dimethylthiazole moiety at N1 forms extensive hydrophobic contacts with the Phe902 shelf, consistent with earlier modelling studies. 
  

Figure 10. (A) Crystal structure of 33f bound to human PARG at 2.25 Å resolution (PBD accession code 6HML). Hydrogen atoms modelled using Maestro (Schrödinger LLC); (B) Protein-ligand interaction diagram with key hydrogen bond interactions highlighted (pink arrows); (C) Overlay of crystal structures of 33f (green carbons and ribbons) with 8a (blue carbons and ribbons), showing maintenance of initial binding mode.
Encouraged by these good levels of potency in the biochemical and cellular assays, we obtained in vitro human microsomal clearance data to assess which derivatives might be candidates for further studies in vivo. Quinazolinediones 34b, 34c, 34e, 34f, bearing a 3-(2-methylthiazol-5-yl)methyl group, showed excellent potency in our biochemical and cellular assays, however, their in vitro microsomal stabilities were poor, which we attributed to their high lipophilicity (e.g., 34f calculated logP38 = 4.7). Despite high intrinsic clearance, 34e has been extensively characterised as a potent and selective chemical probe and used as an in vitro tool compound to study the effects of small molecule inhibition of PARG,12,​[38]​ to evaluate the chemotherapeutic potential of PARG inhibitors. 3-(1-Methylpyrazol-4-yl)methyl derivatives 33a-f maintained a similar level of potency to the 3-(2-methylthiazol-5-yl)methyl compounds, but were slightly less lipophilic (e.g., 33f calculated logP​[39]​ = 3.6), and consequently, showed significantly better stability in human liver microsomes, although clearance remained moderate–high. In contrast to the majority of the 3-(1-methylpyrazol-4-yl)methyl quinazolinediones, 1-oxetan-3-ylmethyl derivative 33d had low clearance in vitro and was a useful candidate for further investigation. 3-(3-Methylisoxazol-5-yl)methyl quinazolinediones 35a-e exhibited a slight reduction in potency in our biochemical and cellular assays compared to 3-(1-methylpyrazol-4-yl)methyl derivatives 33, whilst maintaining a similar level of in vitro microsomal stability. A selection of 3-(5-methyl-1,3,4-thiadiazol-2-yl) and 3-cyanomethyl quinazolinediones 36b-e, 41a and 41e also showed good potency and human microsomal stability, unfortunately, however, their high in vitro mouse clearance precluded them from further studies. 
Cytotoxicity and Selectivity
Pleasingly, all compounds which showed a cell activity of <0.3 μM in this series (exemplified by 33d, 33e, 34e and 35d) showed more than a 100-fold window to cytotoxicity in HeLa cells after 72 h of exposure at PARG cell-active doses.
The selectivity of a set of quinazolinedione derivatives (22f, 33e, 34c, 33e and 35f) was investigated by measuring activity against PARP1 and ARH3, a functionally-related glycohydrolase enzyme. Encouragingly, none of the compounds tested showed any activity in either the PARP1 and ARH3 assays, giving EC50 values of >150 μM and >100 μM, respectively.
Pharmacokinetic investigations
1-Oxetan-3-ylmethyl derivatives 33d and 35d showed no cytotoxicity, and a good balance of cell potency and human and mouse microsomal stability and were therefore selected for further profiling. For the preliminary pharmacokinetic (PK) investigations, mice were dosed intravenously or orally, and tail vein blood samples were analyzed at regular time-points (Table 10).
Table 10. In vitro and in vivo parameters for 33d and 35d 
	33d	35d
Solubility (μM)	>100	>100
Caco2 A–B mean Papp (10-6 cm/s); (efflux ratio)	1.0 (34)	1.9 (21)
Mo Hep CLint (μL/min/106 cells)	24	25
CYP inhibition (IC50, µM, 5 isoforms)a	>10	>25





aCYP1A, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 isoforms tested; bmale CD-1 mice were dosed intravenously (n=2) at a nominal dose level of 1 mg/kg, or orally (n=2) at a nominal dose level of 5 mg/kg. 
The in vivo PK data showed that both compounds were cleared rapidly, with 35d having an IV clearance greater than liver blood flow, indicating that extra-hepatic clearance mechanisms might be involved. Despite this, we were pleased to see moderate levels of bioavailability (F), especially as the in vitro data had shown high hepatocyte clearance, low permeability and high efflux.
CONCLUSION
To date, the elucidation of the precise role of PARG in DNA damage repair and its potential as a novel therapeutic target has been severely limited by the lack of drug-like tool compounds suitable for use in cellular and in vivo models. Starting from a weakly active HTS hit 8a, we have identified several lead-like scaffold hops that show a significant improvement in affinity in biochemical and cellular assays, without the non-specific cellular toxicity of the parent anthraquinone. With the ligand binding site highly solvent-exposed, the tight binding interactions around the N-alkyl sulfonamide moiety of 8a proved to be an essential pharmacophore that was exploited successfully by pursuing a structure-based design approach. An initial virtual screen identified a number of scaffold hops of interest; however, the steep SAR around the sulfonamide necessitated the synthesis of a specific set of N-alkyl groups in order to achieve a satisfactory level of potency. By pursuing a focused library design strategy, a number of structurally diverse bicyclic ring systems were found to be tolerated in the aromatic cleft between Tyr795 and Phe902, with the quinazolinedione scaffold deemed of particular interest based on level of activity, drug-like profile, and potential for further substitution to target additional features on the protein surface. High resolution crystal structures of some key compounds bound to human PARG helped to explain the observed SAR and to guide further design. Excellent levels of potency have been achieved, and in vitro tool compounds such as 34e, with low nanomolar cellular activity, have been provided to elucidate the biological effects of PARG inhibition. These novel PARG inhibitors show no non-mechanistic toxicity, are selective over PARP1 and a functionally-related glycohydrolase (ARH3), and represent promising lead compounds for the discovery of a novel class of chemotherapeutics. Preliminary investigations of 1-oxetan-3-ylmethyl derivatives 33d and 35d in vivo also demonstrated encouraging levels of oral bioavailability. Further progress on these efforts will be reported in due course.
EXPERIMENTAL SECTION
General Chemistry
Flash chromatography was performed using pre-packed silica gel cartridges (KP-Sil SNAP, Biotage, Hengoed UK or RediSep Rf, Isco). Thin layer chromatography was conducted on 5 × 10 cm plates coated with Merck Type 60 F254 silica gel to a thickness of 0.25 mm. All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from the Sigma-Aldrich Chemical Company Ltd. or Fisher Chemicals Ltd., and used without further drying. HPLC grade solvents were obtained from Fisher Chemicals Ltd. All compounds were >95% purity as determined by examination of the LC–MS chromatograms at two independent pHs and the 1H NMR spectra, unless otherwise specifically indicated. Where Cl or Br were present, expected isotopic distribution patterns were observed. Proton (1H) and carbon (13C) NMR spectra were recorded on a 300 MHz Bruker spectrometer. Solutions were typically prepared in either deuterochloroform (CDCl3) or deuterated dimethylsulfoxide (DMSO-d6) with chemical shifts referenced to tetramethylsilane (TMS) or deuterated solvent as an internal standard. 1H NMR data are reported indicating the chemical shift (δ), the integration (e.g., 1H), the multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br., broad; dd, doublet of doublets; etc.) and the coupling constant (J) in Hz (app implies apparent coupling on broadened signals). Deuterated solvents were obtained from Goss. LC–MS analyses were performed on a Waters Acquity UPLC system fitted with BEH C18 1.7 M columns (2.1 × 50 mm) and with UV diode array detection (210–400 nm). Positive and negative mass ion detection was performed using a Waters SQD detector. Analyses were performed with either buffered acidic or basic solvents, with gradients as detailed in the Supporting Information. Some compounds were purified by preparative HPLC on a Waters FractionLynx MS autopurification system, with a Waters XBridge 5 m C18, 100 mm × 19 mm i.d. column, running at a flow rate of 20 mL/min with UV diode array detection (210–400 nm) and mass-directed collection using both positive and negative mass ion detection. Purifications were performed using buffered acidic or basic solvent systems as appropriate.  Compound retention times on the system were routinely assessed using a 30–50 L test injection and a standard gradient, then purified using an appropriately chosen focused gradient as detailed in the Supporting Information, based upon observed retention time. 
Compounds 12d,e, 13c, 16b, 4345 (Table 2) were purchased from either ChemBridge, ChemDiv or Princeton BioMolecular Research.
9,10-Dioxoanthracene-2-sulfonyl chloride (7)
Thionyl chloride (20 mL, 274 mmol) and DMF (1 mL) were sequentially added to 9,10-anthraquinone-2-sulfonic acid, sodium salt, monohydrate (5 g, 16 mmol) in a flask under nitrogen. The reaction mixture was heated at reflux for 2 h.  The reaction mixture was left to cool to ambient temperature overnight and a precipitate formed. The reaction mixture was poured onto stirring ice and EtOAc (50 mL) was added to rinse the flask into the ice solution. The precipitate was filtered and dried in the vacuum oven to yield a pale yellow solid, 7 (2.6 g, 53%). 1H NMR (300 MHz, CDCl3) δ 9.00 (d, J=2.0 Hz, 1H), 8.60 (d, J=8.3 Hz, 1H), 8.35–8.47 (m, 3H), 7.89–7.96 (m, 2H). LC−MS m/z 305.5 [M + H]+. 
N-tert-Butyl-9,10-dioxo-anthracene-2-sulfonamide (8a)
Triethylamine (91 L, 0.65 mmol) and tert-butylamine (68.5 L, 0.65 mmol) were added sequentially to a solution of 7 (100 mg, 0.33 mmol) in DCM (5 mL) at ambient temperature. The reaction mixture was stirred at ambient temperature overnight. The reaction mixture was diluted with DCM (5 mL), washed with water (10 mL) and saturated aq. sodium bicarbonate solution (10 mL). The organic phase was passed through a hydrophobic frit and evaporated to dryness. The crude product was purified by preparative HPLC (high pH) and lyophilized to dryness to yield 8a as a white solid (48 mg, 43%). 1H NMR (300 MHz, DMSO-d6) δ 8.61 (d, J=1.8 Hz, 1H), 8.39 (d, J=8.2 Hz, 1H), 8.31 (dd, J=1.9, 8.1 Hz, 1H), 8.22–8.28 (m, 2H), 7.94–8.02 (m, 3H), 1.14 (s, 9H). 13C NMR (75 MHz, DMSO-d6) δ 181.8, 181.7, 149.3, 135.0, 134.82, 134.77, 133.8, 133.1, 131.3, 128.1, 126.9, 124.4, 53.8, 29.8. HRMS (ESI) m/z [M + Na]+ calcd for C18H17NO4NaS: 366.0770. Found: 366.0765. 
N-Methyl-9,10-dioxo-anthracene-2-sulfonamide (8b)
Methylamine solution (2 M in THF) (0.82 mL, 1.6 mmol) was added dropwise to a solution of 7 (100 mg, 0.33 mmol) in DCM (5 mL) cooled to 0 C. The reaction mixture was allowed to warm to ambient temperature and stirred for 2 h. The reaction mixture was diluted with DCM (5 mL) and washed with water (10 mL), before passing through a hydrophobic frit and evaporating to dryness to yield 8b as a beige solid (76 mg, 77%). 1H NMR (300 MHz, DMSO-d6) δ 8.52 (d, J=1.8 Hz, 1H), 8.42 (d, J=8.1 Hz, 1H), 8.21–8.29 (m, 3H), 7.90–8.03 (m, 3H), 2.48 (d, J=3.7 Hz, 3H). LC−MS m/z 302.1 [M + H]+.
N-Ethyl-9,10-dioxo-anthracene-2-sulfonamide (8c)
Compound 8c was prepared in a manner analogous to that for 8b, purified by preparative HPLC (high pH) (white solid, 26 mg, 26%). 1H NMR (300 MHz, DMSO-d6) δ 8.54 (d, J=1.9 Hz, 1H), 8.41 (d, J=8.2 Hz, 1H), 8.22–8.29 (m, 3H), 7.88–8.02 (m, 3H), 2.86 (q, J=7.2 Hz, 2H), 1.00 (t, J=7.2 Hz, 3H). LC−MS m/z 316.0 [M + H]+.
N-(1,1-Dimethylpropyl)-9,10-dioxo-anthracene-2-sulfonamide (8d)
Compound 8d was prepared in a manner analogous to that for 8b (beige solid, 88 mg, quant.). 1H NMR (300 MHz, CDCl3) δ 8.83 (d, J=1.9 Hz, 1H), 8.46 (d, J=8.2 Hz, 1H), 8.34–8.43 (m, 2H), 8.31 (dd, J=1.9, 8.2 Hz, 1H), 7.85–7.91 (m, 2H), 4.62 (s, 1H), 1.61 (q, J=7.5 Hz, 2H), 1.23 (s, 6H), 0.88 (t, J=7.4 Hz, 3H). LC−MS m/z 356.9 [M  H].  LC-MS purity, 90-95%.
N-(Cyclopropylmethyl)-9,10-dioxo-anthracene-2-sulfonamide (8e) 
Triethylamine (40 L, 0.29 mmol) and cyclopropanemethylamine (23 L, 0.27 mmol) were added sequentially to a solution of 7 (75 mg, 0.24 mmol) in DCM (5 mL) cooled to 0 C. After addition of the reagents the cooling was removed and the reaction mixture was allowed to warm to ambient temperature and stirred for 3 h. The reaction mixture was diluted with DCM (5 mL) and washed with water (10 mL) and saturated aq. sodium bicarbonate solution (10 mL), before passing through a hydrophobic frit and evaporating to dryness. The crude product was purified by automated column chromatography, eluent 0–5% MeOH in DCM to yield 8e as a pale yellow solid (54 mg, 64%). 1H NMR (300 MHz, DMSO-d6) δ 8.56 (d, J=1.6 Hz, 1H), 8.39 (d, J=8.0 Hz, 1H), 8.17–8.32 (m, 4H), 7.94–8.01 (m, 2H), 2.74 (t, J=6.5 Hz, 2H), 0.72–0.86 (m, 1H), 0.29–0.37 (m, 2H), 0.05–0.12 (m, 2H). LC−MS m/z 340.5 [M  H].
N-Cyclopropyl-9,10-dioxo-anthracene-2-sulfonamide (8f) 
Compound 8f was prepared in a manner analogous to that for 8e, stirring at ambient temperature for 1.5 h (pale yellow solid, 39 mg, 49%). 1H NMR (300 MHz, DMSO-d6) δ 8.56 (d, J=1.8 Hz, 1H), 8.43 (d, J=8.1 Hz, 1H), 8.34 (s, 1H), 8.23–8.31 (m, 3H), 7.95–8.01 (m, 2H), 2.16–2.26 (m, 1H), 0.37–0.55 (m, 4H). 13C NMR (75 MHz, DMSO-d6) δ 181.8, 181.7, 145.2, 135.5, 133.8, 133.11, 133.08, 131.9, 128.2, 127.0, 124.9, 117.7, 38.7, 38.5, 24.1, 5.2. HRMS (ESI) m/z [M + Na]+ calcd for C17H13NO4NaS: 350.0457. Found: 350.0449. 
N-Cyclobutyl-9,10-dioxo-anthracene-2-sulfonamide (8g)
Compound 8g was prepared in a manner analogous to that for 8a (beige solid, 60 mg, 77%). 1H NMR (300 MHz, DMSO-d6) δ 8.54 (d, J=1.9 Hz, 1H), 8.39 (d, J=8.1 Hz, 1H), 8.20–8.30 (m, 4H), 7.93–8.03 (m, 2H), 3.72 (quin, J=8.2 Hz, 1H), 1.86–2.00 (m, 2H), 1.65–1.85 (m, 2H), 1.40–1.55 (m, 2H). LC−MS m/z 340.5 [M  H].
N-(1-Methylcyclopropyl)-9,10-dioxo-anthracene-2-sulfonamide (8h)
Triethylamine (181 L, 1.3 mmol) and 1-methylcyclopropanamine hydrochloride (70 mg, 0.65 mmol) were added sequentially to a solution of 7 (100 mg, 0.33 mmol) in DCM (5 mL) at 0 C. The reaction mixture was allowed to warm to ambient temperature and stirred for 1.5 h. The reaction mixture was diluted with DCM (10 mL), 2 M HCl (10 mL) was added and the reaction mixture stirred for 10 min. The organic phase was separated, the aqueous phase further extracted with DCM (10 mL) and the combined organic phase passed through a hydrophobic frit and evaporated to dryness. The resulting solid was triturated with diethyl ether, filtered and dried to yield 8h as a pale yellow solid, (100 mg, 89%). 1H NMR (300 MHz, DMSO-d6) δ 8.55 (d, J=1.9 Hz, 1H), 8.52 (s, 1H), 8.40 (dd, J=0.4, 8.1 Hz, 1H), 8.21–8.29 (m, 3H), 7.93–8.01 (m, 2H), 1.11 (s, 3H), 0.54–0.70 (m, 2H), 0.35–0.51 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 181.74, 181.68, 147.8, 135.3, 134.83, 134.78, 133.8, 133.10, 133.06, 131.4, 128.2, 126.9, 124.5, 124.1, 117.7, 31.1, 24.0, 13.1. HRMS (ESI) m/z [M + Na]+ calcd for C18H15NO4NaS: 364.0614. Found: 364.0607. LC-MS purity, 90-95%.
N-(1-Cyanocyclopropyl)-9,10-dioxo-anthracene-2-sulfonamide (8i)
Triethylamine (75 L, 0.54 mmol) and 1-amino-1-cyclopropanecarbonitrile hydrochloride (32 mg, 0.27 mmol) were added sequentially to a solution of 7 (75 mg, 0.24 mmol) in DCM (5 mL) cooled to 0 C . After addition of the reagents the cooling was removed and the reaction mixture was allowed to warm to ambient temperature and continue stirring. After 5 h, further 1-amino-1-cyclopropanecarbonitrile hydrochloride (32 mg, 0.27 mmol) and triethylamine (75 L, 0.54 mmol) were added to the reaction mixture which was left to stir at ambient temperature for 48 h. LCMS indicated ~50% conversion to the desired product. The reaction mixture was heated at reflux for 5 h, no further conversion to product observed by LCMS. The reaction mixture was diluted with DCM (10 mL) and water (10 mL), separated and the organic phase washed with saturated aq. sodium bicarbonate (10 mL), then passed through a hydrophobic frit and evaporated to dryness. The crude product was purified by preparative HPLC (high pH) to yield 8i as a cream solid (31 mg, 35%). 1H NMR (300 MHz, DMSO-d6) δ 8.58 (d, J=1.6 Hz, 1H), 8.43 (d, J=8.2 Hz, 1H), 8.31 (dd, J=1.9, 8.2 Hz, 1H), 8.23–8.29 (m, 2H), 7.96–8.02 (m, 2H), 1.39–1.45 (m, 2H), 1.20–1.27 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 181.7, 181.5, 144.8, 135.8, 135.0, 134.9, 133.8, 133.04, 132.96, 132.0, 128.4, 127.03, 126.99, 125.1, 119.4, 117.7, 21.9, 15.8. HRMS (ESI) m/z [M + Na]+ calcd for C18H12N2O4S: 375.0410. Found: 375.0403. 
2-[(9,10-Dioxo-2-anthryl)sulfonylamino]acetamide (8j)
Compound 8j was prepared in a manner analogous to that for 8h, stirring at ambient temperature for 4 h, the crude product was purified by preparative HPLC (high pH) (cream solid, 12 mg, 15%). 1H NMR (300 MHz, DMSO-d6) δ 8.55 (d, J=1.7 Hz, 1H), 8.38 (d, J=8.1 Hz, 1H), 8.20–8.30 (m, 4H), 7.93–8.03 (m, 2H), 7.34 (br. s, 1H), 7.05 (br. s, 1H), 3.32 (s, 2H). LC−MS m/z 343.5 [M  H]. LC-MS purity, 90-95%.
3-[(9,10-Dioxo-2-anthryl)sulfonylamino]propanamide (8k)
Compound 8k was prepared in a manner analogous to that for 8h, stirring at ambient temperature for 4 h (pale yellow solid, 27 mg, 32%). 1H NMR (300 MHz, DMSO-d6) δ 8.54 (d, J=1.8 Hz, 1H), 8.41 (d, J=8.1 Hz, 1H), 8.23–8.30 (m, 3H), 8.10 (t, J=5.9 Hz, 1H), 7.94–8.01 (m, 2H), 7.31 (br. s, 1H), 6.83 (br. s, 1H), 2.95–3.05 (m, 2H), 2.23 (t, J=7.3 Hz, 2H). LC−MS m/z 357.5 [M  H]. LC-MS purity, 90-95%.
N-(2-Hydroxyethyl)-9,10-dioxo-anthracene-2-sulfonamide (8l)
Compound 8l was prepared in a manner analogous to that for 8a, the crude product was triturated with DCM/diethyl ether and the filtrate isolated and dried in at 40 C in a vacuum oven (cream solid, 59.5 mg, 79%). 1H NMR (300 MHz, DMSO-d6) δ 8.55 (d, J=1.9 Hz, 1H), 8.40 (d, J=8.1 Hz, 1H), 8.19–8.33 (m, 3H), 8.11 (t, J=5.8 Hz, 1H), 7.93–8.03 (m, 2H), 4.72 (t, J=5.5 Hz, 1H), 3.38 (q, J=6.0 Hz, 2H), 2.88 (q, J=5.9 Hz, 2H). LC−MS m/z 330.2 [M  H].
N-(2-Methoxyethyl)-9,10-dioxo-anthracene-2-sulfonamide (8m)
Compound 8m was prepared in a manner analogous to that for 8a, stirring at ambient temperature for 2 h (cream solid, 42 mg, 53%). 1H NMR (300 MHz, DMSO-d6) δ 8.55 (d, J=1.9 Hz, 1H), 8.39 (d, J=8.1 Hz, 1H), 8.19–8.31 (m, 4H), 7.94–8.01 (m, 2H), 3.30 (t, J=5.6 Hz, 2H), 3.11 (s, 3H), 3.01 (t, J=5.5 Hz, 2H). LC−MS m/z 344.4 [M  H].
N-(2-Methoxy-1,1-dimethyl-ethyl)-9,10-dioxo-anthracene-2-sulfonamide (8n)
Compound 8n was prepared in a manner analogous to that for 8h, stirring at ambient temperature overnight, the crude product was purified by preparative HPLC (high pH) (beige solid, 26 mg, 31%). 1H NMR (300 MHz, DMSO-d6) δ 8.61 (d, J=1.6 Hz, 1H), 8.38 (d, J=8.1 Hz, 1H), 8.21–8.32 (m, 3H), 7.92–8.05 (m, 3H), 3.14 (s, 2H), 2.99 (s, 3H), 1.11 (s, 6H). LC−MS m/z 372.5 [M  H].
N-(2-Cyanoethyl)-9,10-dioxo-anthracene-2-sulfonamide (8o)
Compound 8o was prepared in a manner analogous to that for 8a, stirring at ambient temperature for 2 h (cream solid, 40 mg, 52%). 1H NMR (300 MHz, DMSO-d6) δ 8.49–8.59 (m, 2H), 8.41 (d, J=8.1 Hz, 1H), 8.21–8.34 (m, 3H), 7.93–8.03 (m, 2H), 3.08 (app. q, J=6.2 Hz, 2H), 2.65 (t, J=6.4 Hz, 2H). LC−MS m/z 339.6 [M  H].
1,3-Dimethylquinazoline-2,4(1H,3H)-dione (10a)	
A suspension of benzoyleneurea (2.0 g, 12 mmol) in DMF (24 mL) was treated with potassium carbonate (8.5 g, 62 mmol) and was left to stir, under nitrogen at ambient temperature, for 30 min. The solution was then treated with iodomethane (2.3 mL, 37 mmol) and stirred at ambient temperature for 2 h. The suspension was filtered, water (40 mL) and EtOAc (40 mL) were added to the filtrate. The organic layer was separated, washed with brine (2  20 mL), dried over MgSO4 and concentrated to give 1-10a as a white solid (0.96 g, 41%). 1H NMR (300 MHz, DMSO-d6) δ 8.06 (dd, J=1.7, 7.8 Hz, 1H), 7.81–7.75 (m, 1H), 7.47 (d, J=8.5 Hz, 1H), 7.31 (app. t, J=7.5 Hz, 1H), 3.53 (s, 3H), 3.32 (s, 3H).
1,3-Diethylquinazoline-2,4(1H,3H)-dione (10b)
Compound 10b was prepared in a manner analogous to that for 10a (white solid, 807 mg, 30%). 1H NMR (300 MHz, DMSO-d6) δ 8.07 (dd, J=1.6, 7.9 Hz, 1H), 7.78 (ddd, J=1.8, 7.3, 8.5 Hz, 1H), 7.51 (d, J=8.6 Hz, 1H), 7.30 (app. t, J=7.5 Hz, 1H), 4.15 (q, J=7.2 Hz, 2H), 3.99 (q, J=7.2 Hz, 2H), 1.22 (t, J=7.1 Hz, 3H), 1.16 (t, J=7.1 Hz, 3H).
1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonyl chloride (11a)
Chlorosulfonic acid (1.7 mL, 25 mmol) was added portionwise to stirring 10a (960 mg, 5.1 mmol) cooled to 5–10 C. The reaction mixture was heated at 60 C for 4 h. The reaction mixture was cooled and poured into crushed ice, causing the formation of an off-white precipitate. The precipitate was filtered, washed with water and dried in the vacuum oven to give 11a as a white solid (0.98 g, 67%). 1H NMR (300 MHz, DMSO-d6) δ 8.25 (d, J=2.1 Hz, 1H), 7.93 (dd, J=2.2, 8.7 Hz, 1H), 7.42 (d, J=8.8 Hz, 1H), 3.52 (s, 3H), 3.31 (s, 3H).
1,3-Diethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonyl chloride (11b)
Compound 11b was prepared in a manner analogous to that for 11a (white solid, 657 mg, 64%). 1H NMR (300 MHz, DMSO-d6) δ 8.26 (d, J=2.5 Hz, 1H), 7.92 (dd, J=2.1, 8.7 Hz, 1H), 7.46 (d, J=8.9 Hz, 1H), 4.14 (q, J=6.8 Hz, 2H), 3.99 (q, J=7.0 Hz, 2H), 1.25–1.13 (m, 6H).
N-tert-Butyl-1,3-dimethyl-2,4-dioxo-quinazoline-6-sulfonamide (12a)
11a (100 mg, 0.35 mmol), tert-butylamine (50 L, 0.52 mmol) and triethylamine (0.10 mL, 0.69 mmol) in DCM (5 mL) was stirred at ambient temperature for 1 h. The reaction mixture was diluted with 2 M HCl (5 mL) and DCM (5 mL) and stirred vigorously for 10 min, then filtered through a hydrophobic frit. The organic layer was concentrated to dryness and the crude product purified by preparative HPLC (high pH) to yield 12a as a white solid (83 mg, 73%). 1H NMR (300 MHz, DMSO-d6) δ 8.44 (d, J=2.3 Hz, 1H), 8.12 (dd, J=2.4, 8.9 Hz, 1H), 7.70 (s, 1H), 7.63 (d, J=8.9 Hz, 1H), 3.55 (s, 3H), 3.32 (s, 3H), 1.10 (s, 9H). LC−MS m/z 325.4 [M + H]+.
1,3-Dimethyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (12b)
Compound 12b was prepared in a manner analogous to that for 12a (white solid, 91 mg, 76%). 1H NMR (300 MHz, DMSO-d6) δ 8.41 (d, J=2.3 Hz, 1H), 8.19 (s, 1H), 8.07 (dd, J=2.3, 8.9 Hz, 1H), 7.65 (d, J=8.9 Hz, 1H), 3.56 (s, 3H), 3.33 (s, 3H), 1.07 (s, 3H), 0.49–0.69 (m, 2H), 0.32–0.47 (m, 2H). LC−MS m/z 324.5 [M + H]+. 13C NMR (75 MHz, DMSO-d6) δ 160.7, 150.5, 142.8, 136.7, 132.5, 126.4, 117.7, 115.8, 114.8, 31.0, 30.9, 28.3, 23.9, 12.9. HRMS (ESI) m/z [M + Na]+ calcd for C14H17N3O4NaS: 346.0832. Found: 346.0825. LC-MS purity, 90-95%.
N-(1-Cyanocyclopropyl)-1,3-dimethyl-2,4-dioxo-quinazoline-6-sulfonamide (12c)
Compound 12c was prepared in a manner analogous to that for 12a, the crude product was purified by automated column chromatography, eluent 0100% EtOAc in iso-hexane (white solid, 21 mg, 18%). 1H NMR (300 MHz, DMSO-d6) δ 9.27 (br. s, 1H), 8.46 (s, 1H), 8.13 (d, J=8.9 Hz, 1H), 7.71 (d, J=8.9 Hz, 1H), 3.57 (s, 3H), 1.38–1.54 (m, 2H), 1.15–1.32 (m, 2H). 3H N-CH3 not observed (under water peak). LC−MS m/z 335.5 [M + H]+.
1,3-Diethyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (13a)
Compound 13a was prepared in a manner analogous to that for 12a using 11b, the reaction mixture was stirred at ambient temperature overnight and the crude product purified by automated column chromatography, eluent 0100% EtOAc in iso-hexane (white solid, 52 mg, 47%). 1H NMR (300 MHz, DMSO-d6) δ 8.42 (d, J=2.3 Hz, 1H), 8.20 (s, 1H), 8.06 (dd, J=2.3, 8.9 Hz, 1H), 7.70 (d, J=8.9 Hz, 1H), 4.17 (q, J=6.9 Hz, 2H), 3.99 (q, J=6.9 Hz, 2H), 1.23 (t, J=7.1 Hz, 3H), 1.18 (t, J=7.1 Hz, 3H), 1.08 (s, 3H), 0.52–0.64 (m, 2H), 0.36–0.44 (m, 2H). LC−MS m/z 351.6 [M + H]+.
N-(1-Cyanocyclopropyl)-1,3-diethyl-2,4-dioxo-quinazoline-6-sulfonamide (13b)
Compound 13b was prepared in a manner analogous to that for 12a using 11b, the reaction mixture was heated at 50 C overnight and the crude product purified by automated column chromatography, eluent 0100% EtOAc in iso-hexane (white solid, 36 mg, 44%). 1H NMR (300 MHz, DMSO-d6) δ 9.26 (s, 1H), 8.47 (d, J=2.3 Hz, 1H), 8.12 (dd, J=2.3, 9.0 Hz, 1H), 7.76 (d, J=9.0 Hz, 1H), 4.19 (q, J=7.1 Hz, 2H), 4.00 (q, J=7.0 Hz, 2H), 1.40–1.49 (m, 2H), 1.13–1.31 (m, 8H). LC−MS m/z 363.6 [M + H]+.
N-(1-Methylcyclopropyl)naphthalene-2-sulfonamide (16)
To a solution of 2-naphthylsulfonyl chloride (100 mg, 0.44 mmol) in THF (5 mL) cooled in an ice bath, was added a mixture of N,N-diisopropylethylamine (0.17 mL, 0.95 mmol) and 1-methylcyclopropanamine hydrochloride (0.050 mL, 0.46 mmol) in DCM (3 mL) the mixture was stirred at ambient temperature overnight. The mixture was diluted with water (10 mL) and extracted with DCM (2  10 mL) dried over sodium sulfate and evaporated to dryness. The crude product mixture was purified by preparative HPLC (high pH) to yield 16 as a white solid (50 mg, 43%). 1H NMR (300 MHz, DMSO-d6) δ 8.45 (d, J=1.5 Hz, 1H), 8.09–8.20 (m, 3H), 8.02–8.07 (m, 1H), 7.80 (dd, J=1.9, 8.7 Hz, 1H), 7.64–7.74 (m, 2H), 1.04 (s, 3H), 0.52–0.69 (m, 2H), 0.29–0.43 (m, 2H). LC−MS m/z 262.1 [M + H]+.
3-Methyl-1H-quinazoline-2,4-dione (18)
A solution of 2-amino-N-methylbenzamide (15 g, 0.10 mol) and 1,1-carbonyldiimidazole (21 g, 0.13 mol) in DMF (150 mL) was heated at 135145 °C overnight. The reaction showed 30% starting material by LCMS, so more 1,1-carbonyldiimidazole (14 g, 0.086 mol) was added and the reaction mixture was heated at 140 °C overnight. The reaction showed complete conversion so was cooled and poured into ice/water (300 mL) and stirred for 10 min. The suspension was filtered and the product was washed with water. The solid was dried in the vacuum oven at 50 °C overnight to give 18 as a white solid (16 g, 90%). 1H NMR (300 MHz, DMSO-d6) δ 11.44 (br. s, 1H), 7.93 (dd, J=1.5, 7.8 Hz, 1H), 7.65 (app. t, J=7.7 Hz, 1H), 7.23–7.15 (m, 2H), 3.33 (s, 3H).
3-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonyl chloride (19)
18 (15 g, 0.085 mol) was added portionwise with cooling to chlorosulfonic acid (60 mL, 0.9 mol) maintaining the temperature <20 °C. The reaction mixture was heated to 60 °C and stirred for 2 h then allowed to cool. The reaction mixture was added carefully to ice (500 mL) over 30 min. The resultant precipitate was stirred for 30 min, collected by filtration and washed with water. The solid was dried in the vacuum oven to give 19 as a white solid (23 g, 99%). 1H NMR (300 MHz, DMSO-d6) δ 11.54 (s, 1H), 8.15 (d, J=2.1 Hz, 1H), 7.83 (dd, J=2.0, 8.4 Hz, 1H), 7.13 (d, J=8.5 Hz, 1H), 3.25 (s, 3H).
3-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide (20)
19 (12 g, 44 mmol) and 1‐methylcyclopropanamine hydrochloride (5.2 g, 48 mmol) were slurried in DCM (120 mL) at 20 °C. Triethylamine (13 mL, 96 mmol) was added over 15 min: this was exothermic and the temperature was allowed to rise to 34 °C. As the reaction cooled, a precipitate formed. The mixture was stirred for 2 h at ambient temperature, then 1 M HCl (100 mL) was added and the mixture stirred for 25 min. The product was filtered from the biphasic mixture and washed with water (100 mL). The solid was dried in the vacuum oven to give 20 as a white solid (12 g, 89%). 1H NMR (300 MHz, DMSO-d6) δ 11.83 (br. s, 1H), 8.32 (d, J=2.2 Hz, 1H), 8.13 (s, 1H), 7.99 (dd, J=2.2, 8.6 Hz, 1H), 7.32 (d, J=8.6 Hz, 1H), 1.06 (s, 3H), 0.62–0.55 (m, 2H), 0.42–0.35 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 161.5, 150.2, 141.9, 136.5, 132.5, 126.4, 116.1, 113.7, 30.9, 27.2, 23.9, 13.0. HRMS (ESI) m/z [M + Na]+ calcd for C13H15N3O4NaS: 332.0675. Found: 332.0667. 
N-((3-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)sulfonyl)-N-(1-methylcyclopropyl)acetamide (21)
20 (11 g, 36 mmol) was slurried in pyridine (30 mL) and 4-dimethylaminopyridine (430 mg, 3.5 mmol) was added. Acetic anhydride (34 mL, 356 mmol) was added over 10 min and the resultant thick slurry was stirred overnight at ambient temperature. The reaction mixture was diluted with EtOAc (25 mL) and filtered. The solid was washed with EtOAc (25 mL). The solid was transferred to a conical flask and slurried in water (40 mL) at 60 °C for 2 h. The slurry was cooled to 35 °C and filtered, washing with water (20 mL). The solid was dried in the vacuum oven to give 21 (10 g, 83%). 1H NMR (300 MHz, DMSO-d6) δ 11.91 (br. s, 1H), 8.39 (d, J=2.3 Hz, 1H), 8.09 (dd, J=2.3, 8.7 Hz, 1H), 7.33 (d, J=8.8 Hz, 1H), 3.26 (s, 3H), 2.23 (s, 3H), 1.54 (s, 3H), 1.25–1.16 (m, 2H), 1.10–0.97 (m, 2H).
1-Ethyl-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22a)
Potassium carbonate (47 mg, 0.34 mmol) was added to a solution of 21 (100 mg, 0.28 mmol) and iodoethane (34 L, 0.43 mmol) in DMF (3 mL), the reaction mixture was stirred at ambient temperature overnight, followed by heating at 50 C for 3.5 h. EtOAc (25 mL) and water (25 mL) were added to the reaction mixture, the organic phase was separated, passed through a hydrophobic frit and evaporated to dryness. The crude intermediate was solubilized in THF (5 mL) and conc. aq. NH3 (2 mL) was added, the reaction mixture was heated at 50 C for 29 h. The reaction mixture was evaporated to dryness and the crude product was purified by automated column chromatography, eluent 0–50% EtOAc in iso-hexane to yield 22a as a yellow solid (27 mg, 28%). 1H NMR (300 MHz, CDCl3) δ 8.74 (d, J=2.3 Hz, 1H), 8.15 (dd, J=2.3, 8.9 Hz, 1H), 7.32 (d, J=8.9 Hz, 1H), 4.95 (s, 1H), 4.25 (q, J=7.1 Hz, 2H), 3.51 (s, 3H), 1.39 (t, J=7.2 Hz, 3H), 1.26 (s, 3H), 0.74–0.83 (m, 2H), 0.47–0.55 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.6, 150.0, 141.8, 136.6, 132.6, 126.7, 115.5, 115.0, 30.9, 28.2, 23.9, 13.0, 12.3. HRMS (ESI) m/z [M + Na]+ calcd for C15H19N3O4NaS: 360.0988. Found: 360.0979. 
1-(2-Methoxyethyl)-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22b)
A solution of 21 (75 mg, 0.19 mmol), potassium carbonate (32 mg, 0.23 mmol) and 2-bromoethyl methylether (27 L, 0.29 mmol) in DMF (3 mL) was stirred at ambient temperature overnight. Methanol (3 mL) and potassium carbonate (13 mg, 0.10 mmol) were added to the reaction mixture, which was stirred at ambient temperature for 2 h. Water (10 mL) and brine (10 mL) were added to the reaction mixture, which was then extracted with EtOAc (50 mL), the organic phase was separated, passed through a hydrophobic frit and evaporated to dryness. The crude product was purified by preparative HPLC (high pH) to yield 22b as a white solid (14 mg, 20%). 1H NMR (300 MHz, CDCl3) δ 8.69 (d, J=2.3 Hz, 1H), 8.09 (dd, J=2.3, 9.0 Hz, 1H), 7.53 (d, J=9.0 Hz, 1H), 4.95 (s, 1H), 4.35 (t, J=5.3 Hz, 2H), 3.73 (t, J=5.3 Hz, 2H), 3.49 (s, 3H), 3.32 (s, 3H), 1.24 (s, 3H), 0.73–0.80 (m, 2H), 0.46–0.54 (m, 2H). HRMS (ESI) m/z [M + Na]+ calcd for C16H21N3O5NaS: 390.1094. Found: 390.1084.
1-[2-(Dimethylamino)ethyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22c)
Compound 22c was prepared in a manner analogous to that for 22b (white solid, 18 mg, 25%). 1H NMR (300 MHz, CDCl3) δ 8.73 (d, J=2.3 Hz, 1H), 8.14 (dd, J=2.3, 8.8 Hz, 1H), 7.38 (d, J=8.8 Hz, 1H), 4.96 (s, 1H), 4.30 (t, J=7.3 Hz, 2H), 3.51 (s, 3H), 2.63 (t, J=7.4 Hz, 2H), 2.37 (s, 6H), 1.26 (s, 3H), 0.75–0.81 (m, 2H), 0.47–0.55 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.6, 150.3, 142.1, 136.6, 132.5, 115.7, 114.9, 55.7, 45.5, 41.7, 30.9, 28.3, 23.9, 13.0. HRMS (ESI) m/z [M + H]+ calcd for C17H25N4O4S: 381.1591. Found: 381.1578. 
3-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-1-prop-2-ynyl-quinazoline-6-sulfonamide (22d)
21 (75 mg, 0.19 mmol), propargyl alcohol (22 L, 0.38 mmol) and triphenylphosphine, polymer supported (240 mg, 0.38 mmol) were dissolved in chloroform (3 mL) under nitrogen at ambient temperature. After 2 min, diisopropyl azodicarboxylate (76 L, 0.38 mmol) was added dropwise and the reaction was allowed to stir overnight at ambient temperature. Brine (5 mL) was added to the reaction mixture which was then passed through a hydrophobic frit, the resulting aqueous phase was washed with DCM (10 mL), the organic phase was evaporated to dryness. The resulting oil was solubilized in methanol (3 mL), potassium carbonate (27 mg, 0.19 mmol) was added and the reaction mixture stirred at ambient temperature for 4.5 h. Brine (10 mL) and DCM (20 mL) were added to the reaction mixture, the organic phase was separated with a hydrophobic frit and evaporated to dryness. The crude product was purified by automated column chromatography, eluent 0–80% EtOAc in iso-hexane to yield 22d as a white solid, (62 mg, 93%). 1H NMR (300 MHz, CDCl3) δ 8.74 (d, J=2.3 Hz, 1H), 8.19 (dd, J=2.3, 8.8 Hz, 1H), 7.49 (d, J=8.8 Hz, 1H), 4.99 (d, J=2.5 Hz, 2H), 4.98 (br. s, 1H), 3.52 (s, 3H), 2.36 (t, J=2.5 Hz, 1H), 1.26 (s, 3H), 0.75–0.83 (m, 2H), 0.49–0.56 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.4, 149.9, 141.2, 137.3, 132.5, 126.6, 115.9, 115.2, 78.0, 75.7, 33.5, 30.9, 28.4, 23.9, 13.0. HRMS (ESI) m/z [M + Na]+ calcd for C16H17N3O4NaS: 370.0832. Found: 370.0823. 
1-(Cyanomethyl)-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22e)
20 (50 mg, 0.16 mmol), bromoacetonitrile (12 L, 0.18 mmol) and caesium carbonate (58 mg, 0.18 mmol) in DMF (2 mL) was stirred at ambient temperature for 5 h. Water (10 mL) was added and the reaction mixture extracted with EtOAc (2  10 mL), the combined organic phase was passed through a hydrophobic frit and evaporated to dryness. The crude product was purified by preparative HPLC (high pH) to yield 22e as a pale yellow solid (43 mg, 75%). 1H NMR (300 MHz, DMSO-d6) δ 8.44 (d, J=2.3 Hz, 1H), 8.37 (br. s, 1H), 8.15 (dd, J=2.3, 8.8 Hz, 1H), 7.79 (d, J=8.8 Hz, 1H), 5.34 (s, 2H), 3.32 (s, 3H), 1.08 (s, 3H), 0.56–0.62 (m, 2H), 0.36–0.43 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.4, 150.0, 140.9, 137.8, 132.7, 126.7, 115.7, 115.6, 115.3, 32.3, 31.0, 28.5, 23.9, 13.0. HRMS (ESI) m/z [M + Na]+ calcd for C15H16N4O4NaS: 371.0784. Found: 371.0775. 
1-(Cyclopropylmethyl)-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22f)
Compound 22f was prepared in a manner analogous to that for 22b, purified by automated column chromatography, eluent 0–30% EtOAc in DCM (white solid, 15 mg, 21%). 1H NMR (300 MHz, CDCl3) δ 8.75 (d, J=2.3 Hz, 1H), 8.15 (dd, J=2.3, 8.9 Hz, 1H), 7.44 (d, J=8.9 Hz, 1H), 5.02 (s, 1H), 4.12 (d, J=6.9 Hz, 2H), 3.51 (s, 3H), 1.26 (s, 3H), 0.83–0.75 (m, 2H), 0.64–0.49 (m, 6H). 13C NMR (75 MHz, DMSO-d6) δ 192.6, 160.6, 150.6, 142.2, 136.7, 132.5, 126.7, 117.7, 116.0, 114.9, 47.4, 30.9, 28.4, 23.9, 13.0, 9.4, 3.7. HRMS (ESI) m/z [M + H]+ calcd for C17H22N3O4S: 364.1326. Found: 364.1318. 
1-(Cyclohexylmethyl)-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22g)
Compound 22g was prepared in a manner analogous to that for 22b, the reaction mixture was stirred at ambient temperature for 7 days and purified by automated column chromatography, eluent 0–50% EtOAc in iso-hexane (white solid, 25 mg, 32%). 1H NMR (300 MHz, CDCl3) δ 8.73 (d, J=2.3 Hz, 1H), 8.12 (dd, J=2.3, 8.9 Hz, 1H), 7.29 (d, J=5.0 Hz, 1H), 4.94 (s, 1H), 4.05 (d, J=7.1 Hz, 2H), 3.51 (s, 3H), 1.65–1.85 (m, 6H), 1.27 (s, 3H), 1.15–1.26 (m, 5H), 0.76–0.82 (m, 2H), 0.47–0.56 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.6, 150.6, 142.4, 136.5, 132.3, 126.6, 124.5, 117.7, 116.2, 114.9, 35.8, 30.9, 29.9, 28.4, 25.8, 25.3, 23.9, 13.0. HRMS (ESI) m/z [M + H]+ calcd for C20H28N3O4S: 406.1795. Found: 406.1787. 
1-Benzyl-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22h)
Compound 22h was prepared in a manner analogous to that for 22a (white solid, 101 mg, 88%). 1H NMR (300 MHz, CDCl3) δ 8.73 (d, J=2.3 Hz, 1H), 8.01 (dd, J=2.3, 8.8 Hz, 1H), 7.28–7.40 (m, 4H), 7.21–7.25 (m, 2H), 5.43 (s, 2H), 4.90 (s, 1H), 3.58 (s, 3H), 1.24 (s, 3H), 0.68–0.78 (m, 2H), 0.46–0.53 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.7, 150.9, 142.1, 136.9, 135.8, 132.4, 128.7, 127.3, 126.6, 126.5, 116.0, 115.3, 46.7, 30.9, 28.5, 23.9, 12.9. HRMS (ESI) m/z [M + H]+ calcd for C20H22N3O4S: 400.1326. Found: 400.1316. 
1-[(2-Fluorophenyl)methyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22i)
Compound 22i was prepared in a manner analogous to that for 22a (white powder, 40%). 1H NMR (400 MHz, CDCl3) δ = 8.74 (d, J=2.3 Hz, 1H), 8.04 (dd, J=2.3, 9.2 Hz, 1H), 7.33–7.21 (m, 2H), 7.17–7.09 (m, 3H), 5.48 (s, 2H), 4.88 (s, 1H), 3.58 (s, 3H), 1.24 (s, 3H), 0.78–0.74 (m, 2H), 0.53–0.48 (m, 2H). LC−MS m/z 418.1 [M + H]+.
1-[(3-Fluorophenyl)methyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22j)
Compound 22j was prepared in a manner analogous to that for 22a (white powder, 55%). 1H NMR (400 MHz, CDCl3) δ = 8.72 (d, J=2.3 Hz, 1H), 8.01 (dd, J=2.3, 9.2 Hz, 1H), 7.36–7.29 (m, 1H), 7.16 (d, J=8.7 Hz, 1H), 7.05–6.92 (m, 3H), 5.39 (s, 2H), 4.95 (s, 1H), 3.56 (s, 3H), 1.22 (s, 3H), 0.77–0.72 (m, 2H), 0.52–0.45 (m, 2H). LC−MS m/z 416.0 [M  H].
1-[(4-Fluorophenyl)methyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22k) 
Compound 22k was prepared in a manner analogous to that for 22a (white powder, 28%). 1H NMR (400 MHz, CDCl3) δ = 8.72 (d, J=2.3 Hz, 1H), 8.01 (dd, J=2.3, 9.2 Hz, 1H), 7.28–7.18 (m, 3H), 7.08–7.00 (m, 2H), 5.37 (s, 2H), 4.93 (s, 1H), 3.55 (s, 3H), 1.22 (s, 3H), 0.77–0.71 (m, 2H), 0.52–0.45 (m, 2H). LC−MS m/z 416.1 [M  H].
1-[(2-Methoxyphenyl)methyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22l)
Compound 22l was prepared in a manner analogous to that for 22a (white powder, 17%). 1H NMR (400 MHz, CDCl3) δ = 8.70 (d, J=2.3 Hz, 1H), 7.98 (dd, J=2.3, 9.2 Hz, 1H), 7.31–7.19 (m, 2H), 6.97–6.91 (m, 2H), 6.88–6.82 (m, 1H), 5.40 (s, 2H), 4.90 (s, 1H), 3.94 (s, 3H), 3.56 (s, 3H), 1.22 (s, 3H), 0.78–0.71 (m, 2H), 0.51–0.42 (m, 2H). LC−MS m/z 428.0 [M  H].
1-[(3-Methoxyphenyl)methyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22m)
Compound 22m was prepared in a manner analogous to that for 22a (white powder, 45%). 1H NMR (400 MHz, CDCl3) δ = 8.71 (d, J=1.8 Hz, 1H), 7.99 (dd, J=2.3, 8.7 Hz, 1H), 7.29–7.23 (m, 1H), 7.21 (d, J=8.7 Hz, 1H), 6.85–6.75 (m, 3H), 5.37 (s, 2H), 5.06 (s, 1H), 3.79–3.74 (m, 3H), 3.55 (s, 3H), 1.21 (s, 3H), 0.78–0.70 (m, 2H), 0.50–0.38 (m, 2H). LC−MS m/z 428.0 [M  H].
1-[(4-Methoxyphenyl)methyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22n)
Compound 22n was prepared in a manner analogous to that for 22a (white powder, 20%). 1H NMR (400 MHz, CDCl3) δ = 8.71 (d, J=2.3 Hz, 1H), 8.00 (dd, J=2.3, 8.7 Hz, 1H), 7.29–7.24 (m, 1H), 7.19 (d, J=8.7 Hz, 2H), 6.87 (d, J=8.7 Hz, 2H), 5.34 (s, 2H), 4.90 (s, 1H), 3.78 (s, 3H), 3.55 (s, 3H), 1.22 (s, 3H), 0.77–0.69 (m, 2H), 0.50–0.44 (m, 2H). LC−MS m/z 876.1 [2M + NH4]+.
3-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-1-(2-pyridylmethyl)quinazoline-6-sulfonamide (22o)
Compound 22o was prepared in a manner analogous to that for 22a (white powder, 25%). 1H NMR (400 MHz, CDCl3) δ = 8.69 (d, J=2.3 Hz, 1H), 8.56–8.52 (m, 1H), 8.01 (dd, J=2.3, 8.7 Hz, 1H), 7.66 (dt, J=1.8, 7.8 Hz, 1H), 7.47 (d, J=8.7 Hz, 1H), 7.31 (d, J=8.2 Hz, 1H), 7.22 (t, J=6.1 Hz, 1H), 5.49 (s, 2H), 5.28 (s, 1H), 3.54 (s, 3H), 1.20 (s, 3H), 0.76–0.70 (m, 2H), 0.50–0.42 (m, 2H). LC−MS m/z 401.0 [M + H]+.
3-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-1-(3-pyridylmethyl)quinazoline-6-sulfonamide (22p)
Compound 22p was prepared in a manner analogous to that for 22a (yellow powder, 16%). 1H NMR (400 MHz, CDCl3) δ = 8.73 (d, J=2.3 Hz, 1H), 8.65 (d, J=2.3 Hz, 1H), 8.58 (dd, J=1.4, 5.0 Hz, 1H), 8.04 (dd, J=2.5, 8.9 Hz, 1H), 7.63 (br d, J=8.2 Hz, 1H), 7.34–7.26 (m, 1H), 7.21 (d, J=8.7 Hz, 1H), 5.43 (s, 2H), 4.99 (s, 1H), 3.55 (s, 3H), 1.23 (s, 3H), 0.79–0.69 (m, 2H), 0.54–0.46 (m, 2H). LC−MS m/z 401.0 [M + H]+.
3-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-1-(4-pyridylmethyl)quinazoline-6-sulfonamide (22q)
Compound 22q was prepared in a manner analogous to that for 22a, yellow powder, 27%). 1H NMR (400 MHz, CDCl3) δ = 8.74 (d, J=2.3 Hz, 1H), 8.63–8.57 (m, 2H), 8.02 (dd, J=2.3, 8.7 Hz, 1H), 7.16 (d, J=6.0 Hz, 2H), 7.05 (d, J=8.7 Hz, 1H), 5.41 (s, 2H), 4.96 (s, 1H), 3.56 (s, 3H), 1.23 (s, 3H), 0.77–0.71 (m, 2H), 0.53–0.47 (m, 2H). LC−MS m/z 401.0 [M + H]+.
3-Methyl-N-(1-methylcyclopropyl)-1-[(2-methylpyrazol-3-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (22r)
Compound 22r was prepared in a manner analogous to that for 22d (white powder, 22%). 1H NMR (400 MHz, CDCl3) δ = 8.74 (d, J=2.3 Hz, 1H), 8.10 (dd, J=2.3, 9.2 Hz, 1H), 7.38 (d, J=1.8 Hz, 1H), 7.30 (d, J=8.7 Hz, 1H), 6.00 (d, J=2.3 Hz, 1H), 5.39 (s, 2H), 4.94 (s, 1H), 4.01 (s, 3H), 3.52 (s, 3H), 1.24 (s, 3H), 0.79–0.73 (m, 2H), 0.54–0.47 (m, 2H). LC−MS m/z 404.0 [M + H]+. NMR purity, 85-90%.
1-[(2,5-Dimethylpyrazol-3-yl)methyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22s)
Compound 22s was prepared in a manner analogous to that for 22d (white powder, 13%). 1H NMR (400 MHz, CDCl3) δ = 8.74 (d, J=2.3 Hz, 1H), 8.11 (br dd, J=2.3, 9.2 Hz, 1H), 7.29 (d, J=8.7 Hz, 1H), 5.76 (s, 1H), 5.33 (s, 2H), 4.92 (s, 1H), 3.92 (s, 3H), 3.51 (s, 3H), 2.15 (s, 3H), 1.25 (s, 3H), 0.79–0.74 (m, 2H), 0.53–0.49 (m, 2H). LC−MS m/z 418.1 [M + H]+.
1-[(2,4-Dimethylthiazol-5-yl)methyl]-3-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (22t)
Compound 22t was prepared in a manner analogous to that for 22d (off-white powder, 5%). 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.3 Hz, 1H), 8.22 (s, 1H), 8.11 (dd, J=2.4, 8.9 Hz, 1H), 7.67 (d, J=8.9 Hz, 1H), 5.45 (s, 2H), 3.34 (s, 3H), 2.49 (s, 3H), 2.47 (s, 3H), 1.08 (s, 3H), 0.66–0.56 (m, 2H), 0.43–0.36 (m, 2H). LC−MS m/z 435.5 [M + H]+.
1-Methylquinazoline-2,4(1H,3H)-dione (24)
Sodium cyanate (30 g, 0.46 mol) was added to a slurry of N-methylanthranilic acid (50 g, 0.33 mol) in water (1.75 L) and acetic acid (3.3 mL). The reaction mixture was heated to 50 °C for 1 h. The solution was slowly basified by the addition of sodium hydroxide (exothermic). The resulting solution was heated to 80 °C and stirred overnight. The reaction mixture was cooled to 0 °C and the resultant precipitate collected by filtration. The solid was dissolved in boiling water (200 mL) and acidified with conc. sulfuric acid to pH 2. The slurry was cooled to RT and filtered. The solid was dried in a vacuum oven to give 24 as a white powder (53 g, 77%). 1H NMR (300 MHz, DMSO-d6) δ = 11.54 (br s, 1H), 8.00 (d, J=7.7 Hz, 1H), 7.77 (t, J=7.9 Hz, 1H), 7.43 (d, J=8.6 Hz, 1H), 7.28 (t, J=7.5 Hz, 1H), 3.33 (s, 3H).
1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonyl chloride (25)
Compound 24 (25 g, 0.14 mol) was added portionwise to chlorosulfonic acid (125 mL, 1.9 mol) at 50 °C. The reaction mixture was heated to 50 °C and stirred overnight then allowed to cool. The reaction mixture was added carefully to ice/water (1.5 L) maintaining the temperature <20 °C. The resultant precipitate was collected by filtration and dried in an open atmosphere to give 19 as a white powder (44 g, 113% - contains water). 1H NMR (300 MHz, DMSO-d6) δ = 11.58 (s, 1H), 8.19 (d, J=2.1 Hz, 1H), 7.91 (dd, J=2.1, 8.6 Hz, 1H), 7.38 (d, J=8.7 Hz, 1H), 3.44 (s, 3H). 
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide (26)
 Triethylamine (8.1 g, 80 mmol) was added to a stirred solution of 25 (11.3 g, 36 mmol) in DCM (250 mL). 1‐Methylcyclopropanamine hydrochloride (4.3 g, 40 mmol) was added portionwise over 10 min and the reaction mixture was stirred at RT for 3 h. The reaction mixture was poured onto water (250 mL) and filtered to afford 26 as a white powder (10.5 g, 93%). 1H NMR (300 MHz, DMSO-d6) δ = 11.83 (br s, 1H), 8.35 (d, J=2.4 Hz, 1H), 8.17 (s, 1H), 8.06 (dd, J=2.3, 8.8 Hz, 1H), 7.61 (d, J=8.9 Hz, 1H), 3.48 (s, 3H), 1.07 (s, 3H), 0.64–0.55 (m, 2H), 0.44–0.35 (m, 2H).
Preparation of Compounds 27a–au
General method A:
A solution of 26 (50 mg, 0.16 mmol) in DMF (1 mL) was treated with NaH (60% w/w in mineral oil) (6.6 mg, 0.17 mmol) and the resulting mixture was stirred at RT for 5 min. Alkyl halide, mesylate or tosylate (0.17 mmol) was added (if the alkyl chloride, mesylate or tosylate was used, NaI (5 mg, 0.030 mmol) was also added) and the mixture was stirred at RT until analysis revealed complete reaction. Water (2 mL) and ethyl acetate (3 mL) were added and the layers were separated. The organic layer was washed with water (2  2 mL) and concentrated under reduced pressure. Purification by mass directed prep. HPLC gave the alkylated products.
General method B:
A mixture of 26 (50 mg, 0.161 mmol), polymer supported triphenylphosphine (202 mg, 0.32 mmol) and alcohol (0.32 mmol) in DMF (1.5 mL) was treated with diisopropyl azodicarboxylate (64 μL, 0.32 mmol) and stirred at RT until analysis revealed complete reaction. The reaction mixture was quenched with water (0.5 mL), filtered and washed with EtOAc. The filtrate was concentrated and purified by prep. HPLC to afford the alkylated products.
3-Ethyl-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27a) 
Prepared by General method A (using the alkyl iodide) to afford a white powder, 59%. 1H NMR (300 MHz, CDCl3) δ = 8.73 (d, J=2.3 Hz, 1H), 8.17 (dd, J=2.3, 8.8 Hz, 1H), 7.32 (d, J=8.9 Hz, 1H), 4.97 (s, 1H), 4.18 (q, J=7.0 Hz, 2H), 3.67 (s, 3H), 1.32 (t, J=7.1 Hz, 3H), 1.26 (s, 3H), 0.84–0.71 (m, 2H), 0.56–0.49 (m, 2H). LC−MS m/z 336.6 [M  H].
3-(Cyclopropylmethyl)-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27b)
Prepared by General method A (using the alkyl bromide) to afford a white powder, 18%. 1H NMR (300 MHz, CDCl3) δ = 8.72 (d, J=2.3 Hz, 1H), 8.16 (dd, J=2.3, 8.8 Hz, 1H), 7.32 (d, J=8.9 Hz, 1H), 5.10 (s, 1H), 4.00 (d, J=7.2 Hz, 2H), 3.67 (s, 3H), 1.28–1.22 (m, 4H), 0.81–0.71 (m, 2H), 0.55–0.43 (m, 6H). LC−MS m/z 364.5 [M + H]+.
3-(Cyclohexylmethyl)-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27c)
 Prepared by General method A (using the alkyl bromide) to afford a beige powder, 30%. 1H NMR (300 MHz, CDCl3) δ = 8.63–8.59 (m, 1H), 8.48 (br s, 1H), 8.19–8.12 (m, 1H), 7.32 (d, J=8.9 Hz, 1H), 3.63 (s, 3H), 3.13 (d, J=7.1 Hz, 2H), 1.85–1.65 (m, 7H), 1.28 (s, 3H), 1.24–1.17 (m, 2H), 0.97–0.80 (m, 4H), 0.63 (s, 2H). LC−MS m/z 406.6 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-phenyl-quinazoline-6-sulfonamide (27d)
Following the method of Chan et al.,​[40]​ a mixture of 26 (100 mg, 0.32 mmol), phenylboronic acid (79 mg, 0.65 mmol), copper acetate (59 mg, 0.32 mmol), triethylamine (0.09 mL, 0.65 mmol) and 4 Å molecular sieves was slurried in DCM (2 mL) and stirred at RT for 3 d. The reaction mixture was filtered through celite and the filtrate was concentrated to dryness and partitioned between water (10 mL) and DCM (10 mL). The organic layer was passed through a hydrophobic frit, concentrated to dryness and purified by prep. HPLC to afford 27d (23 mg, 18%) as a white powder. 1H NMR (300 MHz, CDCl3) δ = 8.75 (d, J=2.3 Hz, 1H), 8.23 (dd, J=2.3, 8.8 Hz, 1H), 7.60–7.48 (m, 3H), 7.40 (d, J=8.9 Hz, 1H), 7.32–7.29 (m, 2H), 4.98 (s, 1H), 3.71 (s, 3H), 1.29 (s, 3H), 0.83–0.77 (m, 2H), 0.57–0.52 (m, 2H). LC−MS m/z 386.6 [M + H]+.
3-Benzyl-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27e)
Prepared by General method A (using the alkyl bromide) to afford a white powder, 39%. 1H NMR (300 MHz, CDCl3) δ = 8.51 (s, 1H), 7.93 (br d, J=8.8 Hz, 1H), 7.37–7.24 (m, 2H), 7.17–7.06 (m, 4H), 5.05 (s, 2H), 4.87 (s, 1H), 3.41 (s, 3H), 1.01 (s, 3H), 0.62–0.47 (m, 2H), 0.35–0.22 (m, 2H). LC−MS m/z 400.5 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-(2-pyridylmethyl)quinazoline-6-sulfonamide (27f) 
Prepared by General method A (using the alkyl bromide HBr salt plus an extra equivalent of base) to afford a white powder, 15%. 1H NMR (400 MHz, CDCl3) δ = 8.72 (d, J=2.3 Hz, 1H), 8.50 (br d, J=4.1 Hz, 1H), 8.16 (dd, J=2.3, 8.7 Hz, 1H), 7.66 (dt, J=1.6, 7.7 Hz, 1H), 7.32 (d, J=8.7 Hz, 2H), 7.19–7.13 (m, 1H), 5.42 (s, 2H), 4.92 (s, 1H), 3.66 (s, 3H), 1.25 (s, 3H), 0.79–0.72 (m, 2H), 0.55–0.47 (m, 2H). LC−MS m/z 401.0 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-(3-pyridylmethyl)quinazoline-6-sulfonamide (27g)
Prepared by General method A (using the alkyl bromide HBr salt plus an extra equivalent of base) to afford a white powder, 15%. 1H NMR (400 MHz, CDCl3) δ = 8.81 (br s, 1H), 8.67 (d, J=2.3 Hz, 1H), 8.53 (br d, J=2.3 Hz, 1H), 8.13 (dd, J=2.3, 8.7 Hz, 1H), 7.92 (br d, J=7.8 Hz, 1H), 7.33–7.27 (m, 2H), 5.28 (s, 2H), 5.20 (br s, 1H), 3.64 (s, 3H), 1.21 (s, 3H), 0.80–0.68 (m, 2H), 0.51–0.41 (m, 2H). LC−MS m/z 401.0 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-(4-pyridylmethyl)quinazoline-6-sulfonamide (27h)
 Prepared by General method A (using the alkyl bromide HBr salt plus an extra equivalent of base) to afford a white powder, 19%. 1H NMR (400 MHz, CDCl3) δ = 8.72 (d, J=2.3 Hz, 1H), 8.61–8.52 (m, 2H), 8.22–8.11 (m, 1H), 7.43 (br d, J=5.0 Hz, 2H), 7.32 (d, J=9.2 Hz, 1H), 5.27 (s, 2H), 5.01 (s, 1H), 3.65 (s, 3H), 1.24 (s, 3H), 0.81–0.72 (m, 2H), 0.56–0.45 (m, 2H). LC−MS m/z 401.0 [M + H]+. LC-MS purity, 90-95%.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-phenacyl-quinazoline-6-sulfonamide (27i)
Prepared by General method A (using the alkyl bromide) to afford a white powder, 37%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.24 (s, 1H), 8.18–8.09 (m, 3H), 7.78 –7.72 (m, 2H), 7.65–7.58 (m, 2H), 5.53 (s, 2H), 3.60 (s, 3H), 1.09 (s, 3H), 0.65–0.59 (m, 2H), 0.44–0.38 (m, 2H). LC−MS m/z 428.2 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-[2-oxo-2-(4-pyridyl)ethyl]quinazoline-6-sulfonamide (27j)
Prepared by General method A (using the alkyl bromide HBr salt plus an extra equivalent of base) to afford a white powder, 6%. 1H NMR (300 MHz, DMSO-d6) δ = 8.90 (dd, J=1.6, 4.7 Hz, 2H), 8.42 (d, J=2.3 Hz, 1H), 8.24 (s, 1H), 8.16 (dd, J=2.3, 8.9 Hz, 1H), 7.98 (dd, J=1.8, 4.7 Hz, 2H), 7.75 (d, J=8.9 Hz, 1H), 5.56 (s, 2H), 3.60 (s, 3H), 1.09 (s, 3H), 0.66–0.56 (m, 2H), 0.44–0.39 (m, 2H). LC−MS m/z 429.2 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-prop-2-ynyl-quinazoline-6-sulfonamide (27k)
Prepared by General method B to afford a white powder, 13%. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.3 Hz, 1H), 8.23 (br s, 1H), 8.10 (dd, J=2.3, 8.9 Hz, 1H), 7.68 (d, J=8.9 Hz, 1H), 4.69 (d, J=2.4 Hz, 2H), 3.57 (s, 3H), 3.22–3.17 (m, 1H), 1.07 (s, 3H), 0.64–0.56 (m, 2H), 0.42–0.37 (m, 2H). LC−MS m/z 348.5 [M + H]+.
3-(Cyanomethyl)-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27l)
 Prepared by General method A (using the alkyl bromide) to afford a white powder, 21%. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.3 Hz, 1H), 8.21 (br s, 1H), 8.12 (dd, J=2.3, 8.9 Hz, 1H), 7.70 (d, J=8.9 Hz, 1H), 4.97 (s, 2H), 3.58 (s, 3H), 1.08 (s, 3H), 0.67–0.52 (m, 2H), 0.47–0.34 (m, 2H). LC−MS m/z 349.5 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-(oxetan-3-ylmethyl)-2,4-dioxo-quinazoline-6-sulfonamide (27m)
Prepared by General method A (using the alkyl tosylate) to afford a white powder, 42%. 1H NMR (300 MHz, CDCl3) δ = 8.72 (d, J=2.3 Hz, 1H), 8.18 (d, J=8.9 Hz, 1H), 7.36–7.30 (m, 1H), 4.96 (s, 1H), 4.82–4.74 (m, 2H), 4.71–4.64 (m, 2H), 4.44 (d, J=6.7 Hz, 2H), 3.66 (s, 3H), 3.55–3.38 (m, 1H), 1.27 (s, 3H), 0.81–0.75 (m, 2H), 0.56–0.49 (m, 2H). LC−MS m/z 380.1 [M + H]+.
3-(3-Furylmethyl)-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27n)
Prepared by General method B to afford a white powder, 10%. 1H NMR (300 MHz, CDCl3) δ = 8.72 (d, J=2.3 Hz, 1H), 8.15 (dd, J=2.3, 8.8 Hz, 1H), 7.60 (d, J=0.7 Hz, 1H), 7.34 (t, J=1.6 Hz, 1H), 7.30 (d, J=8.9 Hz, 1H), 6.55 (s, 1H), 5.12 (s, 1H), 5.11 (s, 2H), 3.65 (s, 3H), 1.24 (s, 3H), 0.81–0.73 (m, 2H), 0.54–0.46 (m, 2H). LC−MS m/z 390.1 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-(3-thienylmethyl)quinazoline-6-sulfonamide (27o)
Prepared by General method A (using the alkyl bromide) to afford a white powder, 25%. 1H NMR (300 MHz, DMSO-d6) δ = 8.30 (d, J=2.3 Hz, 1H), 8.06 (br s, 1H), 7.96 (dd, J=2.3, 8.8 Hz, 1H), 7.54 (d, J=8.9 Hz, 1H), 7.36–7.32 (m, 1H), 7.31–7.28 (m, 1H), 6.99 (dd, J=1.3, 4.9 Hz, 1H), 4.99 (s, 2H), 3.44 (s, 3H), 0.95 (s, 3H), 0.51–0.44 (m, 2H), 0.31–0.23 (m, 2H). LC−MS m/z 406.1 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(2-methylthiazol-4-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27p) 
Prepared by General method A (using the alkyl chloride) to afford a white powder, 6%. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.3 Hz, 1H), 8.22 (s, 1H), 8.11 (dd, J=2.3, 8.9 Hz, 1H), 7.68 (d, J=8.9 Hz, 1H), 7.30 (s, 1H), 5.18 (s, 2H), 3.57 (s, 3H), 2.60 (s, 3H), 1.09 (s, 3H), 0.64–0.56 (m, 2H), 0.44–0.37 (m, 2H). LC−MS m/z 421.1 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-(oxazol-4-ylmethyl)-2,4-dioxo-quinazoline-6-sulfonamide (27q)
Following the method of Lipshutz et al.,30 a mixture of 1,3-oxazol-4-ylmethanol (38 mg, 0.39 mmol), 26 (60 mg, 0.19 mmol) and polymer supported triphenylphosphine (242 mg, 0.39 mmol)  in DMF (1 mL) was treated with a solution of bis(4-chlorobenzyl)azodicarboxylate (0.19 mL, 0.39 mmol) in DMF (1 mL) and stirred at RT for 2 h. The reaction mixture was filtered and the filter cake washed with EtOAc (2 × 5 mL). The filtrate was concentrated and then DCM (3 mL) was added. The flask was cooled in an ice bath and the resulting hydrazine by-product was collected by filtration and washed with DCM (2 × 5 mL). The DCM filtrate was concentrated and purified by prep. HPLC to afford 12r (10 mg, 13%) as a white powder. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.3 Hz, 1H), 8.28 (d, J=0.9 Hz, 1H), 8.21 (s, 1H), 8.10 (dd, J=2.3, 8.8 Hz, 1H), 8.04 (d, J=1.0 Hz, 1H), 7.68 (d, J=8.9 Hz, 1H), 5.06 (s, 2H), 3.56 (s, 3H), 1.08 (s, 3H), 0.64–0.56 (m, 2H), 0.44–0.37 (m, 2H). LC−MS m/z 391.1 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-(thiazol-2-ylmethyl)quinazoline-6-sulfonamide (27r)
Prepared by General method B to afford a white powder, 12%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.2 Hz, 1H), 8.34 (s, 1H), 8.12 (dd, J=2.2, 8.9 Hz, 1H), 7.73–7.66 (m, 3H), 5.46 (s, 2H), 3.59 (s, 3H), 1.08 (s, 3H), 0.65–0.57 (m, 2H), 0.44–0.36 (m, 2H). LC−MS m/z 407.5 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-(thiazol-5-ylmethyl)quinazoline-6-sulfonamide (27s)
Prepared by General method B to afford a white powder, 21%. 1H NMR (300 MHz, DMSO-d6) δ = 9.00 (s, 1H), 8.43 (d, J=2.3 Hz, 1H), 8.20 (s, 1H), 8.09 (dd, J=2.3, 8.9 Hz, 1H), 7.93 (s, 1H), 7.66 (d, J=8.9 Hz, 1H), 5.34 (s, 2H), 3.56 (s, 3H), 1.07 (s, 3H), 0.62–0.56 (m, 2H), 0.42–0.36 (m, 2H). LC−MS m/z 407.5 [M + H]+. LC-MS purity, 85-90%.
1-Methyl-N-(1-methylcyclopropyl)-3-[(2-methylthiazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27t)
Prepared by General method B to afford a white powder, 16%. 1H NMR (300 MHz, CDCl3) δ = 8.73 (d, J=2.3 Hz, 1H), 8.16 (dd, J=2.4, 8.9 Hz, 1H), 7.75 (s, 1H), 7.30 (d, J=8.9 Hz, 1H), 5.38 (s, 2H), 4.99 (s, 1H), 3.66 (s, 3H), 2.65 (s, 3H), 1.25 (s, 3H), 0.80–0.74 (m, 2H), 0.55–0.49 (m, 2H). LC−MS m/z 421.0 [M + H]+.
3-[(2-Aminothiazol-5-yl)methyl]-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27u)
1. Preparation of alcohol with protected amino group:
(a) Following the method of Leblanc et al.,​[41]​ a mixture of  methyl 2-aminothiazole-5-carboxylate (359 mg, 2.3 mmol), hexane-2,5-dione (0.29 mL, 2.5 mmol) and p-toluenesulfonic acid monohydrate (20 mg, 0.11 mmol) in toluene (15 mL) was heated to 80 °C for 3 h and then stirred at reflux for a further 17 h. The reaction mixture was then cooled to RT and concentrated. The crude material was columned, eluting with 0–50% EtOAc in hexane, then flushed with EtOAc to give methyl 2-(2,5-dimethylpyrrol-1-yl)thiazole-5-carboxylate as a pale yellow oil (155 mg, 29%) (50% starting material was also recovered). 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (s, 1H), 5.94 (s, 2H), 3.88 (s, 3H), 2.25 (s, 6H).
(b) A solution of methyl 2-(2,5-dimethylpyrrol-1-yl)thiazole-5-carboxylate (1.2 g, 5.0 mmol) in THF (40 mL) was cooled to 0 °C and treated slowly with a solution of lithium aluminium hydride (1.0 M in THF, 5.5 mL, 5.5 mmol) and the mixture was stirred at RT for 20 min. The reaction mixture was cooled to 0 °C and carefully quenched with sat. aq. Rochelle's salt (40 mL) and stirred vigorously at RT for 1 h. The mixture was allowed to settle then the clear solution was decanted away from the sticky residue. The sticky residue was washed with EtOAc and decanted (×3) and the layers separated. The aqueous layer was re-extracted with EtOAc, and organic extracts washed with brine, passed through a hydrophobic frit and concentrated to give an amber oil (989 mg, 96%). 1H NMR (300 MHz, DMSO-d6) δ = 7.65 (t, J=0.9 Hz, 1H), 5.86 (s, 2H), 5.71 (t, J=5.7 Hz, 1H), 4.71 (dd, J=1.0, 5.7 Hz, 2H), 2.19–2.05 (m, 6H). LC-MS purity, 90-95%.
2. Quinazolinedione alkylation:
General method B was followed to afford crude material which was progressed to the deprotection reaction without purification.
3. Deprotection: 
A mixture of the intermediate from the previous step (100 mg, 0.16 mmol), hydroxylamine hydrochloride (171 mg, 2.5 mmol) and 2 M NaOH (0.82 mL, 1.6 mmol) in EtOH (2 mL), water (2 mL) and DMF (2 mL) was heated to reflux for 3 d. The reaction mixture was concentrated and the residue taken up in DCM, then saturated aq. NaHCO3 and water were added, stirred for 5 min and then passed through a hydrophobic frit and washed with DCM. The combined organics were concentrated and the residue purified by prep. HPLC to give 12v (8 mg, 12%) as a white powder. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.4 Hz, 1H), 8.19 (br s, 1H), 8.08 (dd, J=2.3, 8.8 Hz, 1H), 7.65 (d, J=8.9 Hz, 1H), 6.96–6.82 (m, 3H), 5.06 (s, 2H), 3.56 (s, 3H), 1.07 (s, 3H), 0.64–0.53 (m, 2H), 0.45–0.32 (m, 2H). LC−MS m/z 422.2 [M + H]+.
3-[(2,4-Dimethylthiazol-5-yl)methyl]-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27v)
Prepared by General method B to afford a white powder, 4%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.2 Hz, 1H), 8.20 (s, 1H), 8.09 (dd, J=2.2, 8.9 Hz, 1H), 7.65 (d, J=8.9 Hz, 1H), 5.19 (s, 2H), 3.56 (s, 3H), 2.51 (3H, s), 2.44 (s, 3H), 1.07 (s, 3H), 0.67–0.55 (m, 2H), 0.43–0.34 (m, 2H). LC−MS m/z 435.5 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(2-methyl-4-phenyl-thiazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27w)
Prepared by General method B to afford a white powder, 6%. 1H NMR (300 MHz, DMSO-d6) δ = 8.40 (d, J=2.3 Hz, 1H), 8.35 (s, 1H), 8.10 (dd, J=2.3, 8.9 Hz, 1H), 7.77–7.69 (m, 2H), 7.66 (d, J=8.9 Hz, 1H), 7.54–7.37 (m, 3H), 5.41 (s, 2H), 3.54 (s, 3H), 2.59 (s, 3H), 1.08 (s, 3H), 0.64–0.55 (m, 2H), 0.43–0.36 (m, 2H). LC−MS m/z 497.6 [M + H]+.
3-(Isothiazol-5-ylmethyl)-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27x)
Prepared by General method B to afford a white powder, 4%. 1H NMR (300 MHz, DMSO-d6) δ = 8.46–8.42 (m, 2H), 8.21 (s, 1H), 8.13–8.07 (m, 1H), 7.68 (d, J=8.9 Hz, 1H), 7.43 (d, J=1.7 Hz, 1H), 5.41 (s, 2H), 3.57 (s, 3H), 1.08 (s, 3H), 0.63–0.57 (m, 2H), 0.42–0.37 (m, 2H). LC−MS m/z 407.1 [M + H]+. 
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-(thiadiazol-4-ylmethyl)quinazoline-6-sulfonamide (27y)
Prepared by General method B to afford a white powder, 24%. 1H NMR (300 MHz, CDCl3) δ = 8.75 (d, J=2.2 Hz, 1H), 8.65 (s, 1H), 8.19 (dd, J=2.3, 8.8 Hz, 1H), 7.40–7.32 (m, 1H), 5.81 (s, 2H), 4.92 (s, 1H), 3.68 (s, 3H), 1.27 (s, 3H), 0.82–0.74 (m, 2H), 0.57–0.49 (m, 2H). LC−MS m/z 406.5 [M  H].
1-Methyl-N-(1-methylcyclopropyl)-3-[(4-methylthiadiazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27z)
Prepared by General method B to afford a white powder, 50%. 1H NMR (300 MHz, CDCl3) δ = 8.75 (d, J=2.2 Hz, 1H), 8.20 (dd, J=2.3, 8.9 Hz, 1H), 7.34 (d, J=8.9 Hz, 1H), 5.51 (s, 2H), 4.97 (s, 1H), 3.69 (s, 3H), 2.93 (s, 3H), 1.27 (s, 3H), 0.80–0.74 (m, 2H), 0.56–0.50 (m, 2H). LC−MS m/z 422.3 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27aa)
Prepared by General method A (using the alkyl chloride) to afford a white powder, 34%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.23 (s, 1H), 8.12 (dd, J=2.2, 8.9 Hz, 1H), 7.70 (d, J=8.9 Hz, 1H), 5.50 (s, 2H), 3.58 (s, 3H), 2.68 (s, 3H), 1.08 (s, 3H), 0.64–0.56 (m, 2H), 0.44–0.37 (m, 2H). LC−MS m/z 422.1 [M + H]+.
3-(1H-Imidazol-4-ylmethyl)-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27ab)
Prepared by General method B to afford a white powder, 5%. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.3 Hz, 1H), 8.26 (s, 1H), 8.09 (dd, J=2.3, 8.9 Hz, 1H), 7.66 (d, J=8.9 Hz, 1H), 7.48 (d, J=0.9 Hz, 1H), 6.95 (s, 1H), 5.07 (s, 2H), 3.56 (s, 3H), 1.07 (s, 3H), 0.62–0.55 (m, 2H), 0.42–0.36 (m, 2H). LC−MS m/z 390.1 [M + H]+. LC-MS purity, 85-90%.
1-Methyl-N-(1-methylcyclopropyl)-3-[(3-methylimidazol-4-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ac)
Prepared by General method B to afford a white powder, 23%. 1H NMR (300 MHz, CDCl3) δ = 8.73 (d, J=2.3 Hz, 1H), 8.21–8.15 (m, 1H), 7.43 (s, 1H), 7.34–7.30 (m, 2H), 5.27 (s, 2H), 5.00 (s, 1H), 3.87 (s, 3H), 3.66 (s, 3H), 1.26 (s, 3H), 0.82–0.71 (m, 2H), 0.55–0.48 (m, 2H). LC−MS m/z 404.6 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(4-methyl-1,2,4-triazol-3-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ad)
Prepared by General method A (using the alkyl chloride) to afford a white powder, 6%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.40 (s, 1H), 8.23 (s, 1H), 8.13 (dd, J=2.4, 8.9 Hz, 1H), 7.72 (d, J=8.9 Hz, 1H), 5.27 (s, 2H), 3.75 (s, 3H), 3.58 (s, 3H), 1.08 (s, 3H), 0.65–0.57 (m, 2H), 0.44–0.37 (m, 2H). LC−MS m/z 405.2 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(1-methyltetrazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ae)
Prepared by General method A (using the alkyl chloride) to afford a white powder, 30%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.2 Hz, 1H), 8.23 (s, 1H), 8.16–8.11 (m, 1H), 7.72 (d, J=8.9 Hz, 1H), 5.46 (s, 2H), 4.17 (s, 3H), 3.58 (s, 3H), 1.08 (s, 3H), 0.64–0.58 (m, 2H), 0.43–0.38 (m, 2H). LC−MS m/z 406.1 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(3-methyl-1H-pyrazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27af)
Prepared by General method B to afford a white powder, 11%. 1H NMR (300 MHz, CDCl3) δ = 8.70 (d, J=2.3 Hz, 1H), 8.14 (dd, J=2.3, 8.8 Hz, 1H), 7.30 (d, J=9.1 Hz, 1H), 6.15 (s, 1H), 5.84 (s, 1H), 5.26 (s, 2H), 4.68 (br s, 1H), 3.65 (s, 3H), 2.25 (s, 3H), 1.24 (s, 3H), 0.80–0.72 (m, 2H), 0.51–0.44 (m, 2H). LC−MS m/z 402.2 [M  H].
1-Methyl-N-(1-methylcyclopropyl)-3-[(2-methylpyrazol-3-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ag)
Prepared by General method B to afford a white powder, 32%. 1H NMR (400 MHz, CDCl3) δ = 8.71 (d, J=2.3 Hz, 1H), 8.15 (dd, J=2.3, 8.7 Hz, 1H), 7.38 (d, J=1.8 Hz, 1H), 7.30 (d, J=8.7 Hz, 1H), 6.38 (d, J=1.8 Hz, 1H), 5.29 (s, 2H), 4.93 (s, 1H), 4.08 (s, 3H), 3.64 (s, 3H), 1.23 (s, 3H), 0.79–0.73 (m, 2H), 0.55–0.48 (m, 2H). LC−MS m/z 404.0 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(1-methylpyrazol-3-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ah)
Prepared by General method B to afford a white powder, 11%. 1H NMR (300 MHz, CDCl3) δ = 8.75 (d, J=2.3 Hz, 1H), 8.16 (dd, J=2.3, 8.8 Hz, 1H), 7.31 (d, J=8.9 Hz, 1H), 7.28–7.26 (m, 1H), 6.29 (d, J=2.2 Hz, 1H), 5.32 (s, 2H), 4.95 (s, 1H), 3.86 (s, 3H), 3.67 (s, 3H), 1.26 (s, 3H), 0.81–0.75 (m, 2H), 0.55–0.49 (m, 2H). LC−MS m/z 404.6 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ai)
Prepared by General method B to afford a white powder, 9%. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.3 Hz, 1H), 8.19 (br s, 1H), 8.07 (dd, J=2.3, 8.8 Hz, 1H), 7.67 (d, J=5.4 Hz, 1H), 7.64 (d, J=8.9 Hz, 1H), 7.39 (s, 1H), 4.95 (s, 2H), 3.76 (s, 3H), 3.55 (s, 3H), 1.07 (s, 3H), 0.65–0.52 (m, 2H), 0.45–0.33 (m, 2H). LC−MS m/z 404.2 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-3-(1H-pyrazol-4-ylmethyl)quinazoline-6-sulfonamide (27aj)
Prepared by General method B to afford a white powder, 29%. 1H NMR (300 MHz, CDCl3) δ = 8.72 (d, J=2.4 Hz, 1H), 8.15 (dd, J=2.4, 8.9 Hz, 1H), 7.78 (s, 2H), 7.29 (d, J=8.9 Hz, 1H), 5.18 (s, 2H), 4.97 (s, 1H), 3.65 (s, 3H), 2.18 (s, 1H), 1.24 (s, 3H), 0.80–0.74 (m, 2H), 0.54–0.48 (m, 2H). LC−MS m/z 390.4 [M + H]+.
3-[(1-Ethylpyrazol-4-yl)methyl]-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27ak)
Prepared by General method B to afford a white powder, 42%. 1H NMR (300 MHz, CDCl3) δ = 8.73 (d, J=2.3 Hz, 1H), 8.15 (dd, J=2.3, 8.9 Hz, 1H), 7.65 (s, 1H), 7.60 (s, 1H), 7.35–7.30 (m, 1H), 5.13 (s, 2H), 5.06 (br s, 1H), 4.13 (q, J=7.3 Hz, 2H), 3.65 (s, 3H), 1.47 (t, J=7.3 Hz, 3H), 1.25 (s, 3H), 0.82–0.71 (m, 2H), 0.55–0.49 (m, 2H). LC−MS m/z 418.4 [M + H]+.
3-[[1-(Cyanomethyl)pyrazol-4-yl]methyl]-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27al)
A solution of 27ak (45 mg, 0.12 mmol) and sodium hydride (60% w/w in mineral oil, 10 mg, 0.25 mmol) in DMF was stirred at ambient temperature for 30 min. Bromoacetonitrile (8.9 μL, 0.13 mmol) was then added to the reaction mixture, and the reaction mixture stirred at ambient temperature for 1 h. Water (1 mL) was carefully added to the reaction mixture followed by 2 M HCl (1 mL). DCM (10 mL) was added and the mixture was stirred vigorously for 10 min and then passed through a hydrophobic frit. The aqueous layer was washed with DCM (5 mL) and the combined organic phase concentrated to dryness in vacuo. The crude product was purified by prep. HPLC to yield the desired product (6 mg, 12%) as a white powder. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.3 Hz, 1H), 8.08 (dd, J=2.3, 8.9 Hz, 1H), 7.87 (s, 1H), 7.65 (d, J=8.9 Hz, 1H), 7.57 (s, 1H), 5.42 (s, 2H), 4.98 (s, 2H), 3.55 (s, 3H), 1.07 (s, 3H), 0.63–0.54 (m, 2H), 0.43–0.33 (m, 2H). LC−MS m/z 429.3 [M + H]+.
3-(Isoxazol-5-ylmethyl)-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27am)
Prepared by General method A (using the alkyl bromide) to afford a white powder, 29%. 1H NMR (300 MHz, DMSO-d6) δ = 8.50 (d, J=1.8 Hz, 1H), 8.42 (d, J=2.3 Hz, 1H), 8.23 (s, 1H), 8.12 (dd, J=2.3, 8.9 Hz, 1H), 7.70 (d, J=8.9 Hz, 1H), 6.49 (d, J=1.8 Hz, 1H), 5.29 (s, 2H), 3.57 (s, 3H), 1.08 (s, 3H), 0.64–0.56 (m, 2H), 0.43–0.37 (m, 2H). LC−MS m/z 391.2 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(3-methylisoxazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27an)
Prepared by General method B to afford a white powder, 38%. 1H NMR (300 MHz, CDCl3) δ = 8.73 (d, J=2.3 Hz, 1H), 8.19 (dd, J=2.3, 8.8 Hz, 1H), 7.33 (d, J=8.9 Hz, 1H), 6.16 (s, 1H), 5.39 (s, 2H), 4.95 (s, 1H), 3.67 (s, 3H), 2.27 (s, 3H), 1.26 (s, 3H), 0.80–0.75 (m, 2H), 0.55–0.50 (m, 2H). LC−MS m/z 405.2 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(5-methylisoxazol-3-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ao)
Prepared by General method A (using the alkyl bromide) to afford a white powder, 18%. 1H NMR (400 MHz, CDCl3) δ = 8.71 (d, J=2.3 Hz, 1H), 8.16 (dd, J=2.3, 8.7 Hz, 1H), 7.34–7.27 (m, 1H), 6.02 (s, 1H), 5.31 (s, 2H), 4.94 (s, 1H), 3.65 (s, 3H), 2.37 (s, 3H), 1.24 (s, 3H), 0.79–0.72 (m, 2H), 0.53–0.47 (m, 2H). LC−MS m/z 446.0 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(5-methylisoxazol-4-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ap)
Prepared by General method B to afford a white powder, 23%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.38 (s, 1H), 8.08 (dd, J=2.3, 8.9 Hz, 1H), 7.65 (d, J=8.9 Hz, 1H), 4.93 (s, 2H), 3.55 (s, 3H), 2.51 (s, 3H), 1.07 (s, 3H), 0.64–0.55 (m, 2H), 0.43–0.35 (m, 2H). LC−MS m/z 405.1 [M + H]+.
3-[(3,5-Dimethylisoxazol-4-yl)methyl]-1-methyl-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (27aq)
Prepared by General method A (using the alkyl bromide) to afford a white powder, 30%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.07 (dd, J=2.4, 8.9 Hz, 1H), 7.64 (d, J=8.9 Hz, 1H), 4.91 (s, 2H), 3.54 (s, 3H), 2.42 (s, 3H), 2.21 (s, 3H), 1.07 (s, 3H), 0.62–0.56 (m, 2H), 0.41–0.35 (m, 2H). LC−MS m/z 417.0 [M  H].
1-Methyl-N-(1-methylcyclopropyl)-3-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27ar)
Prepared by General method B to afford a white powder, 29%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.25 (s, 1H), 8.15 (dd, J=2.3, 8.9 Hz, 1H), 7.73 (d, J=8.9 Hz, 1H), 5.41 (s, 2H), 3.66–3.52 (m, 3H), 2.30 (s, 3H), 1.09 (s, 3H), 0.65–0.56 (m, 2H), 0.45–0.37 (m, 2H). LC−MS m/z 406.1 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27as)
Prepared by General method B to afford a white powder, 10%. 1H NMR (300 MHz, DMSO-d6) δ = 8.33 (d, J=2.3 Hz, 1H), 8.14 (br s, 1H), 8.04 (dd, J=2.3, 8.9 Hz, 1H), 7.62 (d, J=8.9 Hz, 1H), 5.24 (s, 2H), 3.48 (s, 3H), 2.37 (s, 3H), 0.98 (s, 3H), 0.54–0.47 (m, 2H), 0.34–0.27 (m, 2H). LC−MS m/z 406.2 [M + H]+.
1-Methyl-N-(1-methylcyclopropyl)-3-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (27at)
Prepared by General method B to afford a white powder, 12%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.2 Hz, 1H), 8.22 (s, 1H), 8.15–8.09 (m, 1H), 7.70 (d, J=8.9 Hz, 1H), 5.31 (s, 2H), 3.57 (s, 3H), 2.46 (s, 3H), 1.08 (s, 3H), 0.64–0.57 (m, 2H), 0.43–0.38 (m, 2H). LC−MS m/z 406.1 [M + H]+.
2,4-Dioxo-1H-3,1-benzoxazine-6-sulfonyl chloride (30)
Isatoic acid anhydride 29 (5.0 g, 28 mmol) was added portionwise to stirring chlorosulfonic acid (9 mL, 140 mmol) at RT. A slight exotherm was observed during the addition, and the mixture turned very dark brown immediately. The mixture was heated at 50 °C with a base scrubber for 4 h. The reaction mixture was allowed to cool to RT and then added dropwise to stirring ice/water. The precipitated solid was filtered and oven-dried to give 30 (5.8 g, 79%) as a brown solid. 1H NMR (300 MHz, DMSO-d6) δ = 11.82 (s, 1H), 8.06 (d, J=2.0 Hz, 1H), 7.91 (dd, J=2.0, 8.5 Hz, 1H), 7.11 (d, J=8.5 Hz, 1H).
2-Amino-5-[(1-methylcyclopropyl)sulfamoyl]-N-[(2-methylthiazol-5-yl)methyl]benzamide (31a)
A suspension of 30 (1.0 g, 3.8 mmol) in DMF (12 mL) was treated with 1-methylcyclopropanamine hydrochloride 28 (493 mg, 4.6 mmol) and cooled to −10 °C in an ice/ MeOH bath. The suspension was treated dropwise with triethylamine (1.2 mL, 8.4 mmol) and the resulting solution was stirred at −10 °C for 30 min. A solution of (2-methyl-1,3-thiazol-5-yl)methanamine (400 mg, 3.1 mmol) in DMF (5 mL) was added dropwise to the reaction mixture, followed by triethylamine (1.1 mL, 7.6 mmol) and the reaction mixture was stirred at RT for 18 h. Water (25 mL) was added and the mixture was extracted with EtOAc (2 × 25 mL), the organic extracts were washed with brine (25 mL), dried (hydrophobic frit) and concentrated.  The crude product was purified by automated column chromatography, eluting with 0–5% MeOH in DCM to afford 31a (286 mg, 20%) as an off-white solid. 1H NMR (300 MHz, CDCl3) δ = 7.90 (d, J=2.2 Hz, 1H), 7.62 (dd, J=2.2, 8.8 Hz, 1H), 7.53 (br s, 1H), 7.12 (t, J=6.0 Hz, 1H), 6.70 (d, J=8.8 Hz, 1H), 6.24 (br s, 2H), 5.11 (s, 1H), 4.71 (d, J=5.7 Hz, 2H), 3.08 (s, 1H), 2.68 (s, 3H), 1.18 (s, 3H), 0.80–0.72 (m, 2H), 0.47–0.42 (m, 2H).
2-Amino-5-[(1-methylcyclopropyl)sulfamoyl]-N-[(1-methylpyrazol-4-yl)methyl]benzamide (31b)
Prepared in the same manner as 31a using (1-methyl-1H-pyrazol-4-yl)methylamine, to afford the desired product as a white powder, 67%. 1H NMR (300 MHz, DMSO-d6) δ = 8.83 (t, J=5.7 Hz, 1H), 7.87 (d, J=2.3 Hz, 1H), 7.58 (s, 1H), 7.55 (s, 1H), 7.46 (dd, J=2.2, 8.7 Hz, 1H), 7.35 (s, 1H), 7.09 (br s, 2H), 6.79 (d, J=8.8 Hz, 1H), 4.22 (d, J=5.7 Hz, 2H), 3.78 (s, 3H), 1.04 (s, 3H), 0.65–0.51 (m, 2H), 0.36–0.29 (m, 2H).
2-Amino-5-[(1-methylcyclopropyl)sulfamoyl]-N-[(3-methylisoxazol-5-yl)methyl]benzamide (31c)
Prepared in the same manner as 32a using (3-methylisoxazol-5-ylmethyl)amine, to afford the desired product as an off-white powder, 42%.  1H NMR (300 MHz, CDCl3) δ = 7.95 (d, J=2.1 Hz, 1H), 7.65 (dd, J=2.2, 9.1 Hz, 1H), 6.99 (br s, 1H), 6.72 (d, J=8.6 Hz, 1H), 6.10 (s, 1H), 4.68 (d, J=5.7 Hz, 2H), 2.29 (s, 3H), 1.22 (s, 3H), 0.79–0.75 (m, 2H), 0.49–0.44 (m, 2H).
2-Amino-N-(cyanomethyl)-5-[(1-methylcyclopropyl)sulfamoyl]benzamide (31d)
Prepared in the same manner as 32a, using aminoacetonitrile bisulfate plus an extra equivalent of trimethylamine, to afford the desired product as a white powder, 35%. 1H NMR (300 MHz, CDCl3) δ = 9.18 (t, J=5.4 Hz, 1H), 7.94 (d, J=2.1 Hz, 1H), 7.64 (s, 1H), 7.51 (dd, J=2.1, 8.8 Hz, 1H), 7.24 (s, 2H), 6.85 (d, J=8.9 Hz, 1H), 4.25 (d, J=5.5 Hz, 2H), 1.06 (s, 3H), 0.62–0.56 (m, 2H), 0.38–0.30 (m, 2H).  
N-(1-methylcyclopropyl)-3-[(2-methylthiazol-5-yl)methyl]-2,4-dioxo-1H-quinazoline-6-sulfonamide (32a)
A solution of 31a (283 mg, 0.74 mmol)  in THF (8 mL) was cooled in an ice bath (reaction mixture fitted with NaOH scrubber) and treated with triphosgene (110 mg, 0.37 mmol) which caused precipitation of a white solid. The reaction mixture was stirred at RT for 18 h, then quenched with sat. aq. K2CO3 (10 mL) and stirred for 3 h. The mixture was extracted with EtOAc (3 × 20 mL) and the organic extracts washed with brine, dried (hydrophobic frit) and concentrated to give 17a (275 mg, 91%) as an off-white solid. 1H NMR (300 MHz, DMSO-d6) δ = 11.98 (s, 1H), 8.32 (d, J=2.2 Hz, 1H), 8.14 (s, 1H), 8.01 (dd, J=2.2, 8.6 Hz, 1H), 7.61 (s, 1H), 7.33 (d, J=8.6 Hz, 1H), 5.19 (s, 2H), 1.06 (s, 3H), 0.65–0.51 (m, 2H), 0.45–0.31 (m, 2H).
N-(1-methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-2,4-dioxo-1H-quinazoline-6-sulfonamide (32b)
Prepared from 31b in the same manner as 32a, with an ether trituration, to afford the desired product as a pale yellow solid, 78%. 1H NMR (400 MHz, CD3OD) δ = 8.51 (d, J=2.0 Hz, 1H), 8.05–8.03 (m, 1H), 7.68 (s, 1H), 7.54 (s, 1H), 7.29 (d, J=8.8 Hz, 1H), 5.05 (s, 2H), 3.84 (s, 3H), 1.16 (s, 3H), 0.71–0.67 (m, 2H), 0.43–0.46 (m, 2H). 
N-(1-Methylcyclopropyl)-3-[(3-methylisoxazol-5-yl)methyl]-2,4-dioxo-1H-quinazoline-6-sulfonamide (32c)
Prepared from 31c  in the same manner as 32a to afford the desired product as a white solid, 97%. 1H NMR (400 MHz, DMSO-d6): δ 12.03 (s, 1H), 8.31 (d, J=8.3 Hz, 1H), 8.17 (s, 1H), 8.04–8.02 (m, 1H), 7.36 (d, J=8.8 Hz, 1H), 6.33 (s, 1H), 5.16 (s, 2H), 2.17 (s, 3H), 1.07 (s, 3H), 0.58–0.56 (m, 2H), 0.40–0.37 (m, 2H).  
3-(Cyanomethyl)-N-(1-methylcyclopropyl)-2,4-dioxo-1H-quinazoline-6-sulfonamide (32d)
Prepared from 31d in the same manner as 32a, to afford the desired product as an off-white solid, 84%. 1H NMR (300 MHz, DMSO-d6) δ = 12.13 (s, 1H), 8.33 (d, J=2.2 Hz, 1H), 8.17 (s, 1H), 8.04 (dd, J=2.2, 8.6 Hz, 1H), 7.36 (d, J=8.7 Hz, 1H), 4.91 (s, 2H), 1.07 (s, 3H), 0.68–0.51 (m, 2H), 0.42–0.35 (m, 2H).
Preparation of Compounds 33–36
General method C:
A mixture of 3-substituted quinazolinedione (32a, 32b, 32c or 32d; 0.21 mmol), K2CO3 (34 mg, 0.25 mmol) and alkyl halide, mesylate or tosylate (if the alkyl chloride, mesylate or tosylate was used, NaI (5 mg, 0.030 mmol) was also added) in DMF (2 mL) was heated to 80 °C under microwave irradiation for 20 min. The resulting mixture was diluted with DCM (5 mL) and water (2 mL), stirred vigorously for 10 min, then passed through a hydrophobic frit. The aqueous layer was re-extracted with DCM in a similar manner, and the combined organic extracts were concentrated and purified by prep. HPLC to afford the N1-alkylated product.
1-Ethyl-N-(1-methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (33a)
Prepared by General method C (using the alkyl iodide) using 32b to afford a white powder, 38%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.20 (s, 1H), 8.06 (dd, J=2.3, 8.9 Hz, 1H), 7.70 (d, J=9.0 Hz, 1H), 7.67 (s, 1H), 7.39 (s, 1H), 4.95 (s, 2H), 4.17 (q, J=6.9 Hz, 2H), 3.76 (s, 3H), 1.23 (t, J=7.0 Hz, 3H), 1.07 (s, 3H), 0.62–0.55 (m, 2H), 0.44–0.35 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 160.3, 149.9, 142.3, 139.8, 136.7, 133.3, 128.9, 124.6, 116.5, 115.9, 114.1, 39.4, 38.9, 35.5, 31.8, 24.6, 14.1, 12.6. HRMS (ESI) m/z [M + Na]+ calcd for C19H23N5O4SNa: 440.1363. Found: 440.1350.
N-(1-Methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-2,4-dioxo-1-prop-2-ynyl-quinazoline-6-sulfonamide (33b)
Prepared by General method B, using 32b as a starting material, to afford a white powder, 16%. 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.3 Hz, 1H), 8.24 (br s, 1H), 8.14 (dd, J=2.3, 8.8 Hz, 1H), 7.71 (s, 1H), 7.69 (s, J=7.9 Hz, 1H), 7.40 (s, 1H), 4.99 (d, J=2.2 Hz, 2H), 4.95 (s, 2H), 3.76 (s, 3H), 3.40 (s, 1H), 1.08 (s, 3H), 0.65–0.55 (m, 2H), 0.45–0.35 (m, 2H); HRMS (ESI) m/z [M + H]+ calcd for C20H22N5O4S: 428.1387. Found: 428.1378.
1-(Cyclopropylmethyl)-N-(1-methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (33c)
Prepared by General method B, using 32b as a starting material, to afford a white powder, 17%. 1H NMR (300MHz, DMSO-d6) δ = 8.44 (d, J=2.4 Hz, 1H), 8.38 (s, 1H), 8.07 (dd, J=2.3, 8.9 Hz, 1H), 7.80 (d, J=8.9 Hz, 1H), 7.68 (s, 1H), 7.39 (s, 1H), 4.96 (s, 2H), 4.08 (d, J=6.9 Hz, 2H), 3.76 (s, 3H), 1.24–1.19 (m, 1H), 1.08 (s, 3H), 0.63–0.56 (m, 2H), 0.52–0.44 (m, 4H), 0.42–0.37 (m, 2H); HRMS (ESI) m/z [M + H]+ calcd for C21H26N5O4S: 444.1700. Found: 444.1687.
N-(1-Methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-1-(oxetan-3-ylmethyl)-2,4-dioxo-quinazoline-6-sulfonamide (33d)
Prepared by General method C (using the alkyl tosylate), using 32b as a starting material, to afford a white powder, 43%. 1H NMR (300 MHz, DMSO-d6) δ = 8.41 (d, J=2.3 Hz, 1H), 8.37 (s, 1H), 8.02 (d, J=8.9 Hz, 1H), 7.73–7.66 (m, 2H), 7.39 (s, 1H), 4.95 (s, 2H), 4.61 (dd, J=6.2, 7.8 Hz, 2H), 4.52–4.44 (m, 4H), 3.76 (s, 3H), 3.44–3.39 (m, 1H), 1.07 (s, 3H), 0.59 (s, 2H), 0.42–0.37 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 160.0, 150.7, 142.4, 140.2, 137.2, 133.3, 131.2, 129.1, 116.2, 116.0, 114.0, 74.7, 46.1, 38.9, 35.8, 33.9, 31.8, 24.6, 14.1. HRMS (ESI) m/z [M + H]+ calcd for C21H26N5O5S: 444.1649. Found: 444.1637.
1-[(2,5-Dimethylpyrazol-3-yl)methyl]-N-(1-methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (33e)
Prepared by General method B, using 32b as a starting material, to afford a white powder, 19%. 1H NMR (300MHz, DMSO-d6) δ = 8.44 (d, J=2.3 Hz, 1H), 8.21 (s, 1H), 8.02 (dd, J=2.4, 8.9 Hz, 1H), 7.68 (s, 1H), 7.56 (d, J=8.9 Hz, 1H), 7.39 (s, 1H), 5.73 (s, 1H), 5.37 (s, 2H), 4.97 (s, 2H), 3.82 (s, 3H), 3.76 (s, 3H), 1.99 (s, 3H), 1.07 (s, 3H), 0.62 - 0.55 (m, 2H), 0.42 - 0.35 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 159.9, 150.2, 147.7, 142.0, 140.1, 137.6, 137.0, 133.3, 131.2, 128.8, 116.1, 116.0, 114.8, 105.4, 39.5, 38.9, 36.6, 36.0, 31.8, 24.6, 14.1, 13.2. HRMS (ESI) m/z [M + H]+ calcd for C23H28N7O4S: 498.1918. Found: 498.1905.
1-[(2,4-Dimethylthiazol-5-yl)methyl]-N-(1-methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (33f)
Prepared by General method B, using 32b as a starting material, to afford a white powder, 21%. 1H NMR (300 MHz, CDCl3) δ = 8.72 (d, J=2.3 Hz, 1H), 8.12 (dd, J=2.3, 8.8 Hz, 1H), 7.64 (s, 1H), 7.57 (s, 1H), 7.27–7.25 (m, 1H), 5.40 (s, 2H), 5.14 (s, 2H), 5.08 (s, 1H), 3.87 (s, 3H), 2.59 (s, 3H), 2.57 (s, 3H), 1.26 (s, 3H), 0.80–0.72 (m, 2H), 0.55–0.48 (m, 2H); HRMS (ESI) m/z [M + H]+ calcd for C23H27N6O4S2: 515.1530. Found: 515.1519. LC-MS purity, 90-95%.
N-(1-Methylcyclopropyl)-3-[(2-methylthiazol-5-yl)methyl]-2,4-dioxo-1-prop-2-ynyl-quinazoline-6-sulfonamide (34b)
Prepared by General method B, using 32a as a starting material, to afford a white powder, 75%. 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.2 Hz, 1H), 8.15 (dd, J=2.3, 8.9 Hz, 1H), 7.71 (d, J=8.9 Hz, 1H), 7.64 (s, 1H), 5.25 (s, 2H), 5.00 (d, J=2.4 Hz, 2H), 3.44–3.39 (m, 1H), 2.57 (s, 3H), 1.08 (s, 3H), 0.65–0.54 (m, 2H), 0.48–0.32 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ = 166.2, 159.8, 149.27, 142.5, 141.2, 137.6, 132.9, 131.8, 126.6, 116.2, 115.0, 77.8, 75.9, 37.2, 33.6, 30.9, 23.9, 18.7, 13.0. HRMS (ESI) m/z [M + H]+ calcd for C20H21N4O4S2: 445.0999. Found: 445.0987.
1-(Cyclopropylmethyl)-N-(1-methylcyclopropyl)-3-[(2-methylthiazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (34c)
Prepared by General method B, using 32a as a starting material, to afford a white powder, 34%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.08 (dd, J=2.3, 8.9 Hz, 1H), 7.81 (d, J=8.9 Hz, 1H), 7.62 (s, 1H), 5.25 (s, 2H), 4.09 (d, J=6.9 Hz, 2H), 2.57 (s, 3H), 1.22 (br s, 1H), 1.07 (s, 3H), 0.62–0.56 (m, 2H), 0.53–0.43 (m, 4H), 0.43–0.37 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 160.1, 150.4, 142.7, 137.0, 133.5, 131.8, 128.9, 128.5, 115.6, 114.8, 108.9, 48.4, 37.2, 31.8, 24.7, 18.9, 14.1, 9.4, 4.2. HRMS (ESI) m/z [M + H]+ calcd for C21H25N4O4S2: 461.1312. Found: 461.1299.
1-[(2,5-dimethylpyrazol-3-yl)methyl]-N-(1-methylcyclopropyl)-3-[(2-methylthiazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (34e)
Prepared by General method B, using 32a as a starting material, to afford a white powder, 43%. 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.3 Hz, 1H), 8.21 (br s, 1H), 8.03 (dd, J=2.3, 8.9 Hz, 1H), 7.64 (s, 1H), 7.57 (d, J=8.9 Hz, 1H), 5.75 (s, 1H), 5.38 (s, 2H), 5.27 (s, 2H), 3.82 (s, 3H), 2.58 (s, 3H), 1.99 (s, 3H), 1.07 (s, 3H), 0.58 (s, 2H), 0.39 (d, J=2.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ = 159.8, 150.1, 147.8, 143.1, 142.0, 137.8, 136.4, 133.5, 131.2, 128.8, 123.9, 115.8, 115.0, 105.4, 39.6, 37.4, 36.7, 31.8, 24.6, 19.1, 14.1, 13.3. HRMS (ESI) m/z [M + H]+ calcd for C23H27N6O4S2: 515.1530. Found: 515.1518.
1-[(2,4-Dimethylthiazol-5-yl)methyl]-N-(1-methylcyclopropyl)-3-[(2-methylthiazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (34f)
Prepared by General method B, using 32a as a starting material, to afford an off-white powder, 27%. 1H NMR (300MHz, DMSO-d6) δ = 8.44 (d, J=1.9 Hz, 1H), 8.23 (s, 1H), 8.12 (dd, J=1.8, 8.9 Hz, 1H), 7.67 (s, 1H), 7.64 (s, 1H), 5.46 (s, 2H), 5.26 (s, 2H), 2.58 (s, 3H), 2.49 (s, 3H), 2.47 (s, 3H), 1.07 (s, 3H), 0.58 (s, 2H), 0.44–0.36 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 167.6, 165.3, 159.8, 150.0, 143.0, 141.7, 137.8, 133.6, 131.2, 129.1, 124.7, 124.4, 115.8, 114.4, 40.8, 37.3, 31.9, 24.6, 23.4, 19.1, 15.4, 14.1. HRMS (ESI) m/z [M + H]+ calcd for C23H26N5O4S3 : 532.1141. Found: 532.1129.
1-Ethyl-N-(1-methylcyclopropyl)-3-[(3-methylisoxazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (35a)
Prepared by General method C (using the alkyl iodide), using 32c as a starting material,  to afford a white powder, 26%. 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J=2.3 Hz, 1H), 8.23 (br s, 1H), 8.10 (dd, J=2.2, 8.9 Hz, 1H), 7.75 (d, J=8.9 Hz, 1H), 6.33 (s, 1H), 5.22 (s, 2H), 4.18 (s, 2H), 2.18 (s, 3H), 1.24 (t, J=7.0 Hz, 3H), 1.09 (s, 3H), 0.60 (s, 2H), 0.41 (d, J=2.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ = 166.3, 160.1, 160.0, 149.70, 142.3, 137.1, 133.7, 129.1, 115.6, 114.4, 104.3, 83.6, 39.7, 36.8, 31.8, 24.6, 14.1, 12.5, 11.4. HRMS (ESI) m/z [M + H]+ calcd for C19H23N4O5S: 419.1384. Found: 419.1373.
N-(1-Methylcyclopropyl)-3-[(3-methylisoxazol-5-yl)methyl]-2,4-dioxo-1-prop-2-ynyl-quinazoline-6-sulfonamide (35b)
Prepared by General method C (using the alkyl bromide), using 32c as a starting material, to afford a white powder, 64%. 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.2 Hz, 1H), 8.17 (dd, J=2.3, 8.8 Hz, 1H), 7.74 (d, J=8.9 Hz, 1H), 6.35 (s, 1H), 5.22 (s, 2H), 5.01 (d, J=2.3 Hz, 2H), 3.46–3.40 (m, 1H), 2.18 (s, 3H), 1.09 (s, 3H), 0.64–0.55 (m, 2H), 0.46–0.36 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ = 166.9, 159.9, 159.7, 149.3, 141.3, 137.6, 132.9, 126.7, 116.2, 115.1, 103.5, 77.8, 75.9, 37.2, 33.7, 30.9, 23.9, 13.0, 10.9. HRMS (ESI) m/z [M + Na]+ calcd for C20H20N4O5SNa: 451.1047. Found: 451.1033.
1-(Cyclopropylmethyl)-N-(1-methylcyclopropyl)-3-[(3-methylisoxazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (35c)
Prepared by General method C (using the alkyl bromide), using 32c as a starting material, to afford a white powder, 60%. 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.3 Hz, 1H), 8.24 (s, 1H), 8.11 (dd, J=2.3, 8.9 Hz, 1H), 7.84 (d, J=8.9 Hz, 1H), 6.32 (s, 1H), 5.23 (s, 2H), 4.09 (d, J=6.9 Hz, 2H), 2.18 (s, 3H), 1.30–1.18 (m, 1H), 1.09 (s, 3H), 0.65–0.56 (m, 2H), 0.54–0.35 (m, 6H); 13C NMR (75 MHz, DMSO-d6) δ = 167.0, 160.1, 160.0, 150.0, 142.4, 137.0, 132.9, 126.7, 116.3, 114.7, 103.4, 47.7, 37.1, 30.9, 23.9, 13.0, 10.9, 9.3, 3.7. HRMS (ESI) m/z [M + Na]+ calcd for C21H24N4O5SNa: 467.1360. Found: 467.1349.
N-(1-Methylcyclopropyl)-3-[(3-methylisoxazol-5-yl)methyl]-1-(oxetan-3-ylmethyl)-2,4-dioxo-quinazoline-6-sulfonamide (35d)
Prepared by General method C (using the alkyl tosylate), using 32c as a starting material, to afford a white powder, 42%. 1H NMR (300 MHz, DMSO-d6) δ = 8.42 (d, J=2.3 Hz, 1H), 8.36 (s, 1H), 8.06 (dd, J=2.4, 8.9 Hz, 1H), 7.76 (d, J=9.0 Hz, 1H), 6.33 (s, 1H), 5.21 (s, 2H), 4.61 (dd, J=6.1, 7.8 Hz, 2H), 4.53–4.42 (m, 4H), 3.45–3.39 (m, 1H), 2.18 (s, 3H), 1.09 (s, 3H), 0.60 (s, 2H), 0.43–0.38 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ = 167.0, 160.1, 159.7, 150.4, 142.3, 137.1, 132.7, 126.6, 116.0, 115.0, 103.4, 73.8, 45.7, 37.1, 33.3, 30.9, 24.0, 13.0, 10.9. HRMS (ESI) m/z [M + Na]+ calcd for C21H24N4O6SNa: 483.1309. Found: 483.1296.
1-[(2,5-Dimethylpyrazol-3-yl)methyl]-N-(1-methylcyclopropyl)-3-[(3-methylisoxazol-5-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (35e)
Prepared by General method C (using the alkyl mesylate), using 32c as a starting material, to afford a white powder, 39%. 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.3 Hz, 1H), 8.23 (s, 1H), 8.06 (dd, J=2.3, 8.8 Hz, 1H), 7.60 (d, J=8.9 Hz, 1H), 6.36 (s, 1H), 5.80 (s, 1H), 5.38 (s, 2H), 5.23 (s, 2H), 3.81 (s, 3H), 2.18 (s, 3H), 2.00 (s, 3H), 1.08 (s, 3H), 0.64–0.55 (m, 2H), 0.44–0.36 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 166.0, 160.1, 159.8, 150.1, 147.8, 142.0, 137.9, 136.6, 133.7, 128.8, 115.6, 115.2, 105.4, 104.4, 39.7, 37.0, 36.7, 31.8, 24.6, 14.1, 13.3, 11.4. HRMS (ESI) m/z [M + H]+ calcd for C23H27N6O5S: 499.1758. Found: 499.1747.
3-(Cyanomethyl)-N-(1-methylcyclopropyl)-2,4-dioxo-1-prop-2-ynyl-quinazoline-6-sulfonamide 36b
Prepared by General method C (using the alkyl bromide), using 32d as a starting material, to afford a white powder, 37%.
1H NMR (300 MHz, CDCl3) δ = 8.75 (d, J=2.3 Hz, 1H), 8.25 (dd, J=2.3, 8.9 Hz, 1H), 7.55 (d, J=8.9 Hz, 1H), 5.03–4.95 (m, 5H), 2.41 (t, J=2.4 Hz, 1H), 1.28 (s, 3H), 0.83–0.72 (m, 2H), 0.59–0.50 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 159.2, 148.9, 141.4, 138.3, 134.2, 128.9, 115.5, 115.3, 114.0, 75.7, 74.8, 34.2, 31.9, 29.3, 24.6, 14.1. HRMS (ESI) m/z [M + Na]+ calcd for C17H16N4O4SNa: 395.0784. Found: 395.0776.
3-(Cyanomethyl)-1-(cyclopropylmethyl)-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (36c)
Prepared by General method C (using the alkyl bromide), using 32d as a starting material,  to afford a white powder, 60%. 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.3 Hz, 1H), 8.25 (s, 1H), 8.11 (dd, J=2.3, 8.9 Hz, 1H), 7.85 (d, J=9.0 Hz, 1H), 4.97 (s, 2H), 4.10 (d, J=6.9 Hz, 2H), 2.09 (s, 1H), 1.09 (s, 3H), 0.92–0.78 (m, 1H), 0.65–0.56 (m, 2H), 0.56–0.44 (m, 4H), 0.44–0.36 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 159.7, 149.7, 142.6, 137.6, 134.1, 129.0, 115.2, 115.1, 114.3, 48.9, 31.8, 29.2, 24.6, 14.1, 9.3, 4.2. HRMS (ESI) m/z [M + Na]+ calcd for C18H20N4O4SNa: 411.1097. Found: 411.1088.
3-(Cyanomethyl)-1-[(2,5-dimethylpyrazol-3-yl)methyl]-N-(1-methylcyclopropyl)-2,4-dioxo-quinazoline-6-sulfonamide (36e)
Prepared by General method B, using 32d as a starting material, to afford a white powder, 17%. 1H NMR (300MHz, DMSO-d6) δ = 8.44 (d, J=2.2 Hz, 1H), 8.25 (br s, 1H), 8.06 (dd, J=2.3, 8.9 Hz, 1H), 7.58 (d, J=9.0 Hz, 1H), 5.84 (s, 1H), 5.39 (s, 2H), 4.98 (s, 2H), 3.83 (s, 3H), 2.00 (s, 3H), 1.08 (s, 3H), 0.63–0.55 (m, 2H), 0.43–0.37 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 159.2, 149.4, 148.0, 141.9, 138.3, 136.0, 134.2, 129.0, 115.4, 115.2, 114.0, 105.4, 39.9, 36.7, 31.9, 29.3, 24.6, 14.1, 13.3. HRMS (ESI) m/z [M + Na]+ calcd for C18H20N4O4SNa: 465.1315. Found: 465.1305. 
2-Amino-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]benzamide (37)
(5-Methyl-1,3,4-thiadiazol-2-yl)methanamine 42 (2.4 g, 17 mmol) was added to a magnetically stirred solution of isatoic acid anhydride 29 (2.7 g, 17 mmol) and triethylamine (2.5 mL, 18 mmol) in DMF (20 mL) at 0 °C. After the addition, the resulting mixture was heated to 60 °C for 5 h and then stirred at RT for 16 h. The solvent was removed in vacuo to give a light brown solid, which was preabsorbed onto silica and columned, eluting with 0–5% MeOH/DCM to afford 37 (3.0 g, 65%) as a light brown solid. 1H NMR (300 MHz, DMSO-d6) δ = 9.12 (t, J=5.8 Hz, 1H), 7.51 (dd, J=1.4, 8.0 Hz, 1H), 7.16 (ddd, J=1.5, 7.0, 8.3 Hz, 1H), 6.71 (dd, J=1.1, 8.2 Hz, 1H), 6.59–6.43 (m, 3H), 4.72 (d, J=5.9 Hz, 2H), 2.67 (s, 3H).
3-[(5-Methyl-1,3,4-thiadiazol-2-yl)methyl]-1H-quinazoline-2,4-dione (38)
A solution of 37 (3.0 g, 11 mmol) in THF (100 mL) was cooled to 0 °C and treated with triphosgene (1.6 g, 5.4 mmol), causing precipitate formation. The mixture was stirred in the cool bath for 15 min and then stirred at RT for 18 h. The mixture was quenched with sat. aq. K2CO3 (50 mL) and stirred at RT for 24 h. The resulting precipitate was collected by filtration, washed with water and oven-dried to afford 24 (1.7 g, 58%) as an off-white solid. 1H NMR (300 MHz, DMSO-d6) δ = 11.80 (br s, 1H), 7.96 (d, J=7.8 Hz, 1H), 7.69 (dt, J=1.5, 7.7 Hz, 1H), 7.28–7.16 (m, 2H), 5.44 (s, 2H), 2.67 (s, 3H).
3-[(5-Methyl-1,3,4-thiadiazol-2-yl)methyl]-2,4-dioxo-1H-quinazoline-6-sulfonyl chloride (39)
A solution of 38 (1.7 g, 6.2 mmol) in chlorosulfonic acid (5 mL, 6.2 mmol) was heated to 50 °C for 2 h and then allowed to cool to RT. The reaction mixture was then added dropwise to crushed ice (~20 mL) at −10 °C and stirred for 20 min. The precipitated solid was collected by filtration, washed with water and oven-dried to give a sticky solid. This was azeotroped with toluene (×3) to give the desired product (1.6 g, 69%) as a pale yellow solid. 1H NMR (300 MHz, DMSO-d6) δ = 11.76 (s, 1H), 8.16 (d, J=2.0 Hz, 1H), 7.88 (dd, J=2.0, 8.4 Hz, 1H), 7.17 (d, J=8.5 Hz, 1H), 5.44 (s, 2H), 2.67 (s, 3H).
N-(1-Methylcyclopropyl)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-2,4-dioxo-1H-quinazoline-6-sulfonamide (40)
A mixture of 39 (411 mg, 1.1 mmol) and 1-methylcyclopropanamine hydrochloride (130 mg, 1.2 mmol) in DCM (20 mL) was cooled in an ice bath and treated with triethylamine (0.34 mL, 2.4 mmol). The reaction mixture was allowed to warm to RT and was stirred for 18 h. The reaction mixture was then concentrated, pre-absorbed onto silica and columned, eluting with 0–5% MeOH in DCM afford 40 (142 mg, 32%) as a white powder. 1H NMR (300 MHz, DMSO-d6) δ = 12.07 (s, 1H), 8.33 (s, 1H), 8.16 (s, 1H), 8.04 (br d, J=8.7 Hz, 1H), 7.37 (d, J=8.6 Hz, 1H), 5.44 (s, 2H), 2.68 (s, 3H), 1.07 (s, 3H), 0.63–0.55 (m, 2H), 0.43–0.34 (m, 2H).
1-Ethyl-N-(1-methylcyclopropyl)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (41a)
Prepared by General method C (using the alkyl iodide), using 40 as a starting material, to afford a white powder, 20%. 1H NMR (300 MHz, DMSO-d6) δ = 8.44 (d, J=2.3 Hz, 1H), 8.19 (br s, 1H), 8.11 (dd, J=2.3, 8.9 Hz, 1H), 7.76 (d, J=8.9 Hz, 1H), 5.50 (s, 2H), 4.20 (q, J=7.1 Hz, 2H), 2.68 (s, 3H), 1.24 (t, J=7.0 Hz, 3H), 1.08 (s, 3H), 0.63–0.56 (m, 2H), 0.43–0.37 (m, 2H); HRMS (ESI) m/z [M + H]+ calcd for C18H22N5O4S2: 436.1108. Found: 436.1096.
1-[(2,5-Dimethylpyrazol-3-yl)methyl]-N-(1-methylcyclopropyl)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-2,4-dioxo-quinazoline-6-sulfonamide (41e)
Prepared by General method C (using the alkyl chloride), using 40 as a starting material, to afford a white powder, 44%. 1H NMR (300 MHz, DMSO-d6) δ = 8.45 (d, J=2.3 Hz, 1H), 8.25 (s, 1H), 8.07 (dd, J=2.4, 8.9 Hz, 1H), 7.61 (d, J=8.9 Hz, 1H), 5.79 (s, 1H), 5.52 (s, 2H), 5.40 (s, 2H), 3.82 (s, 3H), 2.68 (s, 3H), 2.00 (s, 3H), 1.08 (s, 3H), 0.63–0.56 (m, 2H), 0.42–0.37 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 166.6, 163.7, 159.8, 150.1, 147.5, 142.0, 138.1, 133.8, 129.0, 124.6, 115.7, 115.1, 105.6, 40.2, 39.7, 36.6, 31.9, 24.7, 15.6, 14.1, 13.0. HRMS (ESI) m/z [M + H]+ calcd for C22H26N7O4S2: 516.1482. Found: 516.1470.

PARG Biochemical Assay
This assay was conducted according to the published protocol.21 Briefly, PARG in vitro assays were conducted in a total volume of 15 µL in a standard 384-well format. 5 µL of human full length PARG (AstraZeneca),16 used at a final reaction concentration of 65 pM, was added to 5 µL of Bt-NAD ribosylated PARP1 substrate (AstraZeneca) at a final reaction concentration of 4.8 nM in assay buffer (50 mM Tris pH 7.4, 0.1 mg/mL BSA, 3 mM EDTA, 0.4 mM EGTA, 1 mM DTT, 0.01% Tween 20, 50 mM KCl). The reaction was incubated at room temperature for 10 min and then 5 µL detection reagent was added. Detection reagent consists of 42 nM MAb anti-6HIS XL665 (CisBio: 61HISXLB) and 2.25 nM streptavidin europium cryptate (CisBio: 610SAKLB), both at 3× working stock concentrations (final concentrations of 14 nM and 0.75 nM respectively), in detection buffer (50 mM Tris pH 7.4, 0.1 mg/mL BSA and 100 mM KF). Following incubation at room temperature for 60 min in the dark, TR-FRET signal was measured at λEx 340 nm and λEm 665 nm and λEm 620 nm using a PHERAstar FS plate reader (BMG Labtech). The ratio was calculated as [Em665/EM620]104 for each well and used to calculate percent inhibition for test compounds.
Cellular PAR chain Assay
This assay was carried out according to the published protocol 31 Briefly, HeLa cells were seeded into 384-well plates and 16–24 h later, were treated with inhibitors (8 pt dose response, 0.01–30 µM) or vehicle (DMSO) control. After 1 h cells were co-dosed with MMS at 50 µg/mL (final) and incubated for 1 h at 37 °C. Cells were fixed with ice-cold 95% methanol/ phosphate buffered saline (PBS) for 15 min at -20 °C and then washed once with PBS at room temperature. Cells were then permeabilized using PBS/Triton 0.1% for 20 min, and washed once in PBS before incubating with anti-PAR antibody (10H, Merck-Millipore) overnight at 4 °C. Cells were then incubated with anti-mouse Alexofluor 488-conjugated secondary antibody (A11029, ThermoFisher) at 1:1000 and Hoechst 33342 (1:5000) and images were captured on a CellInsight (ThermoFisher Scientific, Northumberland, UK) and analyzed using proprietary software. The mean of the intensity of nuclear spots at 488 nM was reported with 25 fields captured from duplicate wells and approximately 1100 cells analyzed per well.
For details of the enzyme assay – cell assay correlation, see Supporting Information Figure S1.
Cytotoxicity Assay
HeLa cells were seeded in 30 µL media at 1×104 cells/mL in Greiner (#781091) 384-well plates. 16–24 h later, cells were treated with inhibitors (8 point dose response, 0.01–30 µM, triplicates) or vehicle (DMSO) control. The outer wells were left un-dosed to account for edge effects. After 72 h, 50 µL of 3.7% formaldehyde/PBS was added to each well and cells were fixed for 20 min. Cells were then rinsed twice with PBS and stained for 1 h with Hoechst 33342/PBS (1:2000) in the dark. After two further rinses with PBS, images were captured and nuclei counted on a CellInsight (ThermoFisher). The maximum number of fields (25) were captured from each triplicate well which approximated to at least 1000 nuclei in vehicle-dosed wells.
Cytotoxicity and Selectivity
See reference 12 for methods to measure PARP1 selectivity and ARH3 selectivity.

Pharmacokinetics
All studies were conducted after review by the Animal Welfare and Ethical Review Body at CRUK-MI and in accordance with the University of Manchester Policy on the use of animals in research.  All work was carried out in compliance with the Animals (Scientific Procedures) Act 1986 and EU Directive 2010/63/EU.
Pharmacokinetics were studied in male CD-1 mice following single intravenous or oral administration.  Compounds were formulated as solutions comprising up to 10% DMSO with up to 10% Tween80 in saline at a concentration of approximately 1 mM.  Doses were administered at 1 mg/kg (IV) or 5 mg/kg (oral).  Blood samples were collected as dried blood spots and assayed following solvent extraction through a phospholipid removal plate followed by LC-MS/MS analysis. The time-points for blood collection were as follows: oral (0.5, 1, 3, 5 and 24 h); IV (0.1, 0.25, 0.75, 2, 5 and 24 h).  The resulting concentration-time data were analyzed by non-compartmental methods (PK Solver, Excel Add-In).

Structure-based Virtual screening and Library Design
The X-ray crystal structure of the anthraquinone 8a in complex with the human PARG catalytic domain (PDB 6HMM) was the basis for virtual screening and protein-ligand docking studies using the Schrödinger modelling suite (Schrödinger, LLC, New York, NY, 2012-2015 releases). The Maestro Protein Preparation Wizard was used for initial processing of the X-ray crystal structure, applying default settings for hydrogen addition, optimization of hydrogen bonding networks and constrained geometry refinement, followed by visual assessment of the final protein model. Crystallographic solvent molecules were removed prior to generation of a receptor grid file for use in Glide docking. A grid box was defined based on the crystallographic pose of 8a, extending the inner grid box to 14 Å in the direction of the PARG ribose-binding site so as to encompass the bound pose of ADP-ribose and hence to facilitate docking of ligands larger than the relatively compact anthraquinone 8a. Hydrogen bonding constraint sites were defined as the protein atoms interacting with the sulfonamide moiety of 8a (Glu727 carboxylate, Gln754 sidechain NH2, Ile726 backbone NH).
For the initial virtual screen, a set of commercially available aryl sulfonamides was generated by searching an in-house compilation of individual supplier catalogues, filtered for general drug-like property profiles.27  Prompted by the steep SAR we had observed around the sulfonamide moiety of 8a, the substructure search was limited to aryl sulfonamides bearing a small N-alkyl substituent, as represented by the SMILES string cS(=O)(=O)[NH]CC. After removal of duplicates and checking of physicochemical property profiles using Canvas, a set of approximately 30,000 compounds was prepared for docking using LigPrep and subsequently docked to the PARG protein grid using Glide SP, using default docking parameters other than inclusion of at least one of the H-bonding constraints around the sulfonamide moiety. From the docked poses, a selection was made on the basis of docking score, visually plausible binding interactions, lead-like property profile and chemical diversity.
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